<html lang="en" class="pb-page js" data-request-id="94d6bf7a523b1aed-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6bf7a523b1aed-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/Z2c6l9xzVNry6bTynrZsEIJxAfQVmTnCaWIbXl_Ja_U9nAzpdIDnEnCxobwH9eTd4Bsr8lIRKywRnID-gmFRrg=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6bf7a523b1aed-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.11561659822476944"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Viral Infections|Vaccines|Infectious Disease General|Global Health">
<meta name="Specialties" content="Infectious Disease"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2108903","title":"EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge","category":"Research","type":"Original Article","topics":"Viral Infections|Vaccines|Infectious Disease General|Global Health","specialties":"Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-02-17T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Viral Infections|Vaccines|Infectious Disease General|Global Health\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2108903","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"RSV Inhibitor EDP-938 in a Human Virus Challenge","doi":"10.1056/NEJMdo006434","issueDate":"2022-02-17T00:00Z","age":"6Months-1990","isFree":"y","topics":"Viral Infections|Vaccines|Infectious Disease General|Global Health","viewType":"Full","specialties":"Infectious Disease"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6bf7a523b1aed-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge"><meta name="dc.Creator" content="Alaa Ahmad"><meta name="dc.Creator" content="Kingsley Eze"><meta name="dc.Creator" content="Nicolas Noulin"><meta name="dc.Creator" content="Veronika Horvathova"><meta name="dc.Creator" content="Bryan Murray"><meta name="dc.Creator" content="Mark Baillet"><meta name="dc.Creator" content="Laura Grey"><meta name="dc.Creator" content="Julie Mori"><meta name="dc.Creator" content="Nathalie Adda"><meta name="dc.Description" content="Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality among infants, older adults, and immunocompromised adults. EDP-938, a nonfusion replication inhibitor of RSV, ..."><meta name="Description" content="Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality among infants, older adults, and immunocompromised adults. EDP-938, a nonfusion replication inhibitor of RSV, ..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-02-17"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2108903"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202202173860709"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2118465"><meta name="dc.Relation" content="YXQYoa2108903"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2108903">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2108903">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2108903">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge | NEJM">
        <meta property="og:title" content="EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2108903">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/65155284-a088-4147-9214-36dbeb3f8404/nejmoa2108903_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/65155284-a088-4147-9214-36dbeb3f8404/nejmoa2108903_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality
among infants, older adults, and immunocompromised adults. EDP-938, a nonfusion replication
inhibitor of RSV, ...">
        <meta name="twitter:description" content="Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality
among infants, older adults, and immunocompromised adults. EDP-938, a nonfusion replication
inhibitor of RSV, ...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3272">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2108903">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2108903">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2108903;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms;issue:issue:doi\:10.1056/nejm_2022.386.issue-7">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2108903" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2108903" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2108903" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2108903" class="inputDoi"><input type="hidden" value="A. Ahmad and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;386:655-666" class="inputCitation"><input type="hidden" value="02-16-2022" class="inputEPubDate"><input type="hidden" value="February 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6bf7a523b1aed-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Alaa</span> <span property="familyName">Ahmad</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kingsley</span> <span property="familyName">Eze</span>, <span property="honorificSuffix">B.Sc.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nicolas</span> <span property="familyName">Noulin</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Veronika</span> <span property="familyName">Horvathova</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bryan</span> <span property="familyName">Murray</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mark</span> <span property="familyName">Baillet</span>, <span property="honorificSuffix">B.Sc., C.Stat.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Laura</span> <span property="familyName">Grey</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Julie</span> <span property="familyName">Mori</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Nathalie</span> <span property="familyName">Adda</span>, <span property="honorificSuffix">M.D.</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">February 16, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">386</span></span>:<span property="pageStart">655</span>-<span property="pageEnd">666</span></div><div class="doi">DOI: 10.1056/NEJMoa2108903</div><div class="core-enumeration"><a href="/toc/nejm/386/7"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">386</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">7</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAlaa%2BAhmad%252C%2BKingsley%2BEze%252C%2BNicolas%2BNoulin%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D7%26contentID%3D10.1056%252FNEJMoa2108903%26title%3DEDP-938%252C%2Ba%2BRespiratory%2BSyncytial%2BVirus%2BInhibitor%252C%2Bin%2Ba%2BHuman%2BVirus%2BChallenge%26publicationDate%3D02%252F17%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2108903" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAlaa%2BAhmad%252C%2BKingsley%2BEze%252C%2BNicolas%2BNoulin%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D7%26contentID%3D10.1056%252FNEJMoa2108903%26title%3DEDP-938%252C%2Ba%2BRespiratory%2BSyncytial%2BVirus%2BInhibitor%252C%2Bin%2Ba%2BHuman%2BVirus%2BChallenge%26publicationDate%3D02%252F17%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/ce13f0f9-9846-4c73-bd64-71507103babf/nejmoa2108903.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2108903.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2108903" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2108903" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2108903.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Respiratory syncytial virus (RSV) infection causes substantial morbidity and mortality among infants, older adults, and immunocompromised adults. EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In a two-part, phase 2a, randomized, double-blind, placebo-controlled challenge trial, we assigned participants who had been inoculated with RSV-A Memphis 37b to receive EDP-938 or placebo. Different doses of EDP-938 were assessed. Nasal-wash samples were obtained from day 2 until day 12 for assessments. Clinical symptoms were assessed by the participants, and pharmacokinetic profiles were obtained. The primary end point was the area under the curve (AUC) for the RSV viral load, as measured by reverse-transcriptase–quantitative polymerase-chain-reaction assay. The key secondary end point was the AUC for the total symptom score.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">In part 1 of the trial, 115 participants were assigned to receive EDP-938 (600 mg once daily [600-mg once-daily group] or 300 mg twice daily after a 500-mg loading dose [300-mg twice-daily group]) or placebo. In part 2, a total of 63 participants were assigned to receive EDP-938 (300 mg once daily after a 600-mg loading dose [300-mg once-daily group] or 200 mg twice daily after a 400-mg loading dose [200-mg twice-daily group]) or placebo. In part 1, the AUC for the mean viral load (hours×log<sub>10</sub> copies per milliliter) was 204.0 in the 600-mg once-daily group, 217.7 in the 300-mg twice-daily group, and 790.2 in the placebo group. The AUC for the mean total symptom score (hours×score, with higher values indicating greater severity) was 124.5 in the 600-mg once-daily group, 181.8 in the 300-mg twice-daily group, and 478.8 in the placebo group. The results in part 2 followed a pattern similar to that in part 1: the AUC for the mean viral load was 173.9 in the 300-mg once-daily group, 196.2 in the 200-mg twice-daily group, and 879.0 in the placebo group, and the AUC for the mean total symptom score was 99.3, 89.6, and 432.2, respectively. In both parts, mucus production was more than 70% lower in each EDP-938 group than in the placebo group. The four EDP-938 regimens had a safety profile similar to that of placebo. Across all dosing regimens, the EDP-938 median time to maximum concentration ranged from 4 to 5 hours, and the geometric mean half-life ranged from 13.7 to 14.5 hours.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">All EDP-938 regimens were superior to placebo with regard to lowering of the viral load, total symptom scores, and mucus weight without apparent safety concerns. (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03691623" target="_blank">NCT03691623</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo006434/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo006434" data-multimedia-filename="NEJMdo006434_600x400.jpg">
                <img src="/cms/asset/99f26760-a463-4b78-ab2a-bac54c8053a6/media/NEJMdo006434_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo006434" data-multimedia-filename="NEJMdo006434_600x400.jpg">RSV Inhibitor EDP-938 in a Human Virus Challenge</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Respiratory syncytial virus (RSV) infection is a global health challenge that causes substantial morbidity and mortality among infants, older adults, and immunocompromised adults.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4" id="body-ref-r4-1" href-manipulated="true">1-4</a></sup> Among U.S. adults, an estimated 177,000 hospitalizations and 14,000 deaths associated with RSV infections occur annually.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup> However, the greatest burden of disease occurs among infants and young children, with over 57,000 hospitalizations and 500,000 emergency department visits among children younger than 5 years of age.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-3" href-manipulated="true" aria-label="Reference 4">4</a></sup> In addition to RSV-associated hospitalizations and emergency department visits, outpatient visits for RSV represent approximately 80% of RSV cases across all age groups.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-2" href-manipulated="true" aria-label="Reference 2">2</a></sup> Globally, RSV infections in children younger than 5 years of age are estimated to cause 3.2 million hospitalizations and 94,600 to 149,400 deaths, primarily in the developing world.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5" href-manipulated="true" aria-label="Reference 5">5</a></sup></div><div role="paragraph">The only approved therapy for RSV is aerosolized ribavirin. However, approved use is limited to hospitalized infants and young children with severe lower-airway disease caused by RSV, and it is rarely administered owing to its unfavorable safety profile, teratogenic potential, and questionable clinical efficacy.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7" id="body-ref-r7" href-manipulated="true">6,7</a></sup> Palivizumab, an RSV-specific monoclonal antibody, is approved only for the prevention of serious lower respiratory tract disease caused by RSV in high-risk pediatric patients, such as premature infants and those with particular cardiac and pulmonary conditions.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8" href-manipulated="true" aria-label="Reference 8">8</a></sup> Because of the substantial morbidity and mortality estimates among infants, older adults, and immunocompromised adults, there is a strong need for a safe and effective RSV therapy.</div><div role="paragraph">EDP-938 is a nonfusion replication inhibitor of RSV that acts by modulating the viral nucleoprotein (N protein).<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10" id="body-ref-r10-1" href-manipulated="true">9,10</a></sup> Findings from in vitro time-of-addition studies suggest that EDP-938 would be effective even after the virus has entered a cell, a feature that is distinct from RSV fusion inhibitors.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-2" href-manipulated="true" aria-label="Reference 10">10</a></sup> In RSV-infected African green monkeys, an analysis of bronchoalveolar lavage and nasopharyngeal swab samples showed that EDP-938 reduced RSV viral load by more than 4 log<sub>10</sub> as compared with vehicle control.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-3" href-manipulated="true" aria-label="Reference 10">10</a></sup> Pharmacokinetic data from the first-in-human study showed that EDP-938 was rapidly absorbed, with little accumulation (accumulation ratio, &lt;1.5, calculated by dividing the AUC for the plasma concentration of EDP-938 at steady state by the AUC on day 1), and had a mean half-life ranging from 11 to 18 hours across multiple dosing regimens.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-1" href-manipulated="true" aria-label="Reference 11">11</a></sup> Multiple oral doses of EDP-938 of up to 600 mg once daily or 300 mg twice daily were administered for 7 days without evident safety concerns.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-2" href-manipulated="true" aria-label="Reference 11">11</a></sup> This RSV challenge trial evaluated the safety and pharmacokinetic and antiviral activity of multiple oral doses of EDP-938 administered to healthy participants who were intranasally inoculated with RSV-A Memphis 37b (M37b).</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Procedures</h3><div role="paragraph">This phase 2a, randomized, double-blind, placebo-controlled, human virus challenge trial was conducted in two parts. In part 1, the trial was powered to assess reductions in both RSV viral load and clinical symptoms; part 2 was planned to be initiated after completion and review of the data from part 1 and was powered for RSV viral load. The participants were 18 to 55 years of age and were assessed as being healthy and serosuitable for the RSV challenge (i.e., they had serum titers of preexisting RSV-A M37b–specific antibodies of ≤810, which represented the lowest 25th percentile of the screened population). After screening, eligible participants were confined to a specialized quarantine unit managed by hVIVO until discharge on day 12. Before inoculation with RSV-A M37b, quarantined participants underwent additional screening to exclude those with respiratory pathogens. On day 0, participants were inoculated intranasally with the RSV-A M37b challenge virus (a 0.8-ml dose containing approximately 4 log<sub>10</sub> plaque-forming units).</div><div role="paragraph">The decision to start EDP-938 dosing was based on the detection of RSV by qualitative integrated cycler polymerase-chain-reaction (PCR) assay (3M Integrated Cycler, Focus Diagnostics)<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup> in nasal-wash samples from day 2 through the morning of day 5. Once RSV infection was identified by qualitative integrated cycler PCR, the participant was randomly assigned to one of three trial groups and received the first dose of EDP-938 or placebo. If RSV infection had not been identified in a participant by the morning of day 5, the participant was randomly assigned to a trial group and received the first dose 12 hours later. The participants in each group received 10 doses of EDP-938 or placebo over a 5-day period. In part 1, the participants were randomly assigned in a 1:1:1 ratio to receive a once-daily 600-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 600-mg once-daily group), a 500-mg loading dose of EDP-938 followed by a 300-mg second dose 11 to 13 hours later and then 300 mg of EDP-938 twice daily (the 300-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours. The regimens used in part 2 were selected on the basis of the safety, pharmacokinetic, and efficacy data from part 1. In part 2, the participants were randomly assigned in a 1:1:1 ratio to receive a 600-mg loading dose of EDP-938 followed by placebo 11 to 13 hours later and then a once-daily 300-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 300-mg once-daily group), a 400-mg loading dose of EDP-938 followed by a 200-mg second dose 11 to 13 hours later and then 200 mg of EDP-938 twice daily (the 200-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours. The participants were discharged on day 12 if they had a negative RSV antigen test and were followed up until day 28. Details regarding the design and conduct of the trial, the eligibility criteria, and the statistical methods are provided in the <a href="#ap1">protocol</a> and the statistical analysis plan, both available with the full text of this article at NEJM.org.</div></section><section id="sec-1-2"><h3>Trial Oversight</h3><div role="paragraph">The trial was conducted in accordance with the Declaration of Helsinki (1996 version), the International Conference on Harmonisation Good Clinical Practice guidelines, applicable regional and local regulations, and the trial protocol, which was approved by an independent ethics committee (research ethics reference number, 18/YH/0328). All the participants provided written informed consent.</div><div role="paragraph">The trial was designed and sponsored by Enanta Pharmaceuticals and managed by hVIVO Services. Data analysis was performed by statisticians at S-Cubed Biometrics in conjunction with the authors. The authors interpreted the data and participated in the preparation of the manuscript, with the support of a medical writing team at Venn Life Sciences (an affiliate of hVIVO Services), and the authors and sponsor made the decision to submit the manuscript for publication. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the <a href="#ap1">protocol</a>.</div></section><section id="sec-1-3"><h3>Assessments</h3><div role="paragraph">Nasal-wash samples were obtained twice daily from day 2 until the morning of day 12 for qualitative and quantitative RSV assessments. Clinical symptoms were assessed (on a scale of 0 to 3, with a higher score indicating greater severity) by the participants with the use of a 10-item diary card (see the <a href="#ap1">protocol</a>) three times per day beginning immediately before RSV-A M37b inoculation (day 0) and continuing through the morning of day 12. Safety was assessed throughout the trial. Blood samples were collected at prespecified time points for laboratory testing and assessment of EDP-938 plasma concentrations through a validated bioanalytic method. Additional details regarding the assessments are provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The prespecified primary efficacy end point was the area under the curve (AUC) for the RSV viral load, as measured by reverse-transcriptase–quantitative PCR (RT-qPCR) assay of the nasal-wash samples from the participants inoculated with RSV-A M37b. The key secondary end point was the AUC for the total symptom score obtained from the 10-item diary card. Other secondary end points were the total weight of nasal mucus; the AUC for the RSV viral load, as measured in the nasal-wash samples by cell-based infectivity (plaque) assay; safety; and pharmacokinetic measures. The AUC was calculated by means of the trapezoid rule, which incorporated the actual time of the assessments.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup></div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">Assuming a 70% reduction in the AUC for the RSV viral load (coefficient of variation, 56%), we calculated that a sample of 12 participants who could be evaluated (i.e., those with confirmed RSV infection) per group would provide part 1 of the trial with 80% power to detect a significant difference between the EDP-938 groups and the placebo group with respect to the primary end point at a two-sided significance level of 0.05. Furthermore, assuming a 70% reduction in the AUC for the total symptom score (coefficient of variation, 79%), we estimated that 21 participants per group would be required to provide 80% power to detect a significant difference between the EDP-938 groups and the placebo group with respect to clinical symptoms. To account for a 56% rate of infection among inoculated participants and for a dropout rate of less than 1% during the postinoculation period, we planned to recruit 38 participants per group. The results of part 1 showed that a sample of 21 participants per group would be sufficient for part 2.</div><div role="paragraph">All participants were first inoculated with RSV-A M37b, regardless of whether they would receive a dose of EDP-938 or placebo; hence, all the participants were included in the safety analysis population. The intention-to-treat (ITT)–infected analysis population included the participants who had been inoculated with RSV-A M37b, had received at least one dose of EDP-938 or placebo, and had confirmed infection, defined as at least two positive viral load RT-qPCR assays specific for the challenge virus reported over two consecutive trial days or a positive viral load RT-qPCR assay specific for the challenge virus and a positive cell-based infectivity assay of the same sample.</div><div role="paragraph">The primary and key secondary efficacy end points were prospectively defined and compared across the trial groups in the ITT-infected analysis population by fitting an analysis-of-covariance model, with the trial group as the main effect and the baseline value of the end-point measure as the covariate. The trial focused on safety and pharmacokinetics, and therefore no adjustment for multiplicity was made. Thus, a P value is shown only for the primary end point, and point estimates and 95% confidence intervals are shown for other end points. All P values are two-sided.</div><div role="paragraph">In general, data were rarely missing and were not imputed, and summary statistics were reported on the basis of the observed data. The primary and secondary AUC end points were derived with the use of all collected nonmissing data between receipt of the first dose of EDP-938 and day 12. To reduce the potential effect of missing data, participants were included only if they had at least one measurement available on each day from the first dose of EDP-938 to day 12. None of the participants lacked this criterion, and all were included in the analysis of the AUC end points. RT-qPCR values that were not detected or were below the limit of quantification were assigned substitution values, as shown in section 15.1 in the statistical analysis plan. For adverse events with incomplete or missing dates of onset, it was assumed that the event had occurred during the treatment period, unless the stop date for adverse events indicated otherwise. Additional details regarding the statistical analysis are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Participants</h3><div role="paragraph">In part 1 of the trial, 115 participants were quarantined, inoculated, and randomly assigned to a trial group. One participant did not receive EDP-938 owing to anxiety after inoculation but remained in quarantine and completed trial assessments to day 12. In part 2, a total of 63 participants were quarantined, inoculated, and randomly assigned to a trial group. An additional participant was quarantined and inoculated but withdrew consent before randomization. The ITT-infected analysis populations included 86 participants in part 1 and 38 participants in part 2. The baseline characteristics of the participants in the safety analysis population were similar across all trial groups in parts 1 and 2 (<a href="#t1">Table 1</a>). Information on the extent to which the trial participants represented the general population with RSV disease is provided in Table S1 in the <a href="#ap2">Supplementary Appendix</a>. The trial sample was considered to be representative of the general RSV adult population with no underlying medical conditions.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t1.jpg"><img src="/cms/10.1056/NEJMoa2108903/asset/faac943e-e432-48af-b05a-2fa154c7a92a/assets/images/large/nejmoa2108903_t1.jpg" height="1928" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Participants</th><th class="txxx-borders" colspan="4"><span>Part 1<a href="#t1fn2" role="doc-noteref">†</a></span></th><th class="txxr-borders" colspan="4"><span>Part 2<a href="#t1fn3" role="doc-noteref">‡</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">600-mg<br>Once-Daily Group</th><th class="xxxx-borders">300-mg<br>Twice-Daily Group</th><th class="xxxx-borders">Placebo<br>Group</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">300-mg<br>Once-Daily Group</th><th class="xxxx-borders">200-mg<br>Twice-Daily Group</th><th class="xxxx-borders">Placebo<br>Group</th><th class="xxxr-borders">Total</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Were inoculated — no.</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">38</td><td class="xxxx-borders shading">38</td><td class="xxxx-borders shading">115</td><td class="xxxx-borders shading">21</td><td class="xxxx-borders shading">21</td><td class="xxxx-borders shading">21</td><td class="xxxr-borders shading">63</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Underwent randomization — no.</td><td class="xxxx-borders">39</td><td class="xxxx-borders">38</td><td class="xxxx-borders">38</td><td class="xxxx-borders">115</td><td class="xxxx-borders">21</td><td class="xxxx-borders">21</td><td class="xxxx-borders">21</td><td class="xxxr-borders">63</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Were included in the ITT analysis population — no. (%)</td><td class="xxxx-borders shading">38 (97)</td><td class="xxxx-borders shading">38 (100)</td><td class="xxxx-borders shading">38 (100)</td><td class="xxxx-borders shading">114 (99)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxr-borders shading">63 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Completed trial — no. (%)</td><td class="xxxx-borders">39 (100)</td><td class="xxxx-borders">38 (100)</td><td class="xxxx-borders">38 (100)</td><td class="xxxx-borders">115 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxr-borders">63 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Were included in the ITT-infected analysis population — no. (%)</td><td class="xxxx-borders shading">25 (64)</td><td class="xxxx-borders shading">31 (82)</td><td class="xxxx-borders shading">30 (79)</td><td class="xxxx-borders shading">86 (75)</td><td class="xxxx-borders shading">15 (71)</td><td class="xxxx-borders shading">11 (52)</td><td class="xxxx-borders shading">12 (57)</td><td class="xxxr-borders shading">38 (60)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Were included in the PK analysis population — no. (%)</td><td class="xxxx-borders shading">38 (97)</td><td class="xxxx-borders shading">38 (100)</td><td class="xxxx-borders shading">38 (100)</td><td class="xxxx-borders shading">114 (99)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxr-borders shading">63 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Were included in the safety analysis population — no. (%)</td><td class="xxxx-borders">39 (100)</td><td class="xxxx-borders">38 (100)</td><td class="xxxx-borders">38 (100)</td><td class="xxxx-borders">115 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxr-borders">63 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">28.5±5.84</td><td class="xxxx-borders shading">27.2±7.50</td><td class="xxxx-borders shading">27.6±7.86</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">23.4±3.22</td><td class="xxxx-borders shading">24.4±5.83</td><td class="xxxx-borders shading">23.1±5.54</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">25 (66)</td><td class="xxxx-borders shading">20 (53)</td><td class="xxxx-borders shading">25 (66)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">11 (52)</td><td class="xxxx-borders shading">10 (48)</td><td class="xxxx-borders shading">12 (57)</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Female</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">18 (47)</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">10 (48)</td><td class="xxxx-borders">11 (52)</td><td class="xxxx-borders">9 (43)</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Race — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Asian</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">White</td><td class="xxxx-borders">33 (87)</td><td class="xxxx-borders">32 (84)</td><td class="xxxx-borders">31 (82)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">18 (86)</td><td class="xxxx-borders">17 (81)</td><td class="xxxx-borders">19 (90)</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23 shading" data-xml-align="left">Other</td><td class="xbxx-borders shading">4 (11)</td><td class="xbxx-borders shading">4 (11)</td><td class="xbxx-borders shading">3 (8)</td><td class="xbxx-borders shading">—</td><td class="xbxx-borders shading">2 (10)</td><td class="xbxx-borders shading">2 (10)</td><td class="xbxx-borders shading">2 (10)</td><td class="xbxr-borders shading">—</td></tr></tbody></table></div><figcaption><div class="caption">Analysis Populations and Baseline Characteristics of the Participants in Trial Parts 1 and 2.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SDs. The intention-to-treat (ITT) analysis population included the participants who were inoculated with respiratory syncytial virus A Memphis 37b (RSV-A M37b), underwent randomization, and received at least one dose of EDP-938 or placebo. The ITT-infected analysis population included the participants in the ITT analysis population who had confirmed RSV-A M37b infection. The pharmacokinetic (PK) analysis population included the participants in the ITT analysis population who had at least one available post-dose PK result. The safety analysis population included all the participants who were inoculated with RSV-A M37b, regardless of whether they would receive a dose of EDP-938 or placebo.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">In part 1 of the trial, 115 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a once-daily 600-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 600-mg once-daily group), a 500-mg loading dose of EDP-938 followed by a 300-mg second dose 11 to 13 hours later and then 300 mg of EDP-938 twice daily (the 300-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">In part 2 of the trial, 63 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a 600-mg loading dose of EDP-938 followed by placebo 11 to 13 hours later and then a once-daily 300-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 300-mg once-daily group), a 400-mg loading dose of EDP-938 followed by a 200-mg second dose 11 to 13 hours later and then 200 mg of EDP-938 twice daily (the 200-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Race was reported by the participants.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph">In part 1, the AUC for the mean RSV viral load, as measured by RT-qPCR assay and expressed as hours×log<sub>10</sub> copies per milliliter (the primary end point), was significantly lower in the EDP-938 groups than in the placebo group (204.0 in the 600-mg once-daily group, 217.7 in the 300-mg twice-daily group, and 790.2 in the placebo group) (<a href="#t2">Table 2</a>). The 95% confidence interval for the least-squares mean difference from placebo was negative in the EDP-938 groups, with P&lt;0.001 for each comparison. The mean RSV viral load decreased faster and earlier in the EDP-938 groups than in the placebo group (<a href="#f1">Figure 1</a>). There was little difference between the two EDP-938 groups.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2108903_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2108903_f1.jpg"><img src="/cms/10.1056/NEJMoa2108903/asset/65155284-a088-4147-9214-36dbeb3f8404/assets/images/large/nejmoa2108903_f1.jpg" height="3272" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Viral Load, Clinical Symptoms, and Mucus Weight in Trial Parts 1 and 2.</div><div class="notes"><div role="doc-footnote">Shown are the mean (±SE) respiratory syncytial virus loads, total symptom scores, and mucus weight from the time immediately before administration of the first dose until 10 days afterward in the intention-to-treat–infected analysis population, which included the participants who had been inoculated with the respiratory syncytial virus A Memphis 37b strain, had received at least one dose of EDP-938 or placebo, and had confirmed infection. In part 1 of the trial, 115 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a once-daily 600-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 600-mg once-daily group), a 500-mg loading dose of EDP-938 followed by a 300-mg second dose 11 to 13 hours later and then 300 mg of EDP-938 twice daily (the 300-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours. In part 2 of the trial, 63 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a 600-mg loading dose of EDP-938 followed by placebo 11 to 13 hours later and then a once-daily 300-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 300-mg once-daily group), a 400-mg loading dose of EDP-938 followed by a 200-mg second dose 11 to 13 hours later and then 200 mg of EDP-938 twice daily (the 200-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours. The total symptom score is the sum of the scores for all 10 symptoms that were listed in the diary card and assessed by the participants 3 times daily. The score for each symptom ranged from 0 to 3, with higher scores indicating greater severity (additional details are provided in Section 10.7.2.1 of the statistical analysis plan, available with the <a href="#ap1">protocol</a> at NEJM.org). CBI denotes cell-based infectivity, PFU plaque-forming unit, and RT-qPCR reverse-transcriptase–quantitative polymerase chain reaction.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t2.jpg"><img src="/cms/10.1056/NEJMoa2108903/asset/6f54b883-2ebe-4474-810f-ed45e5dddef2/assets/images/large/nejmoa2108903_t2.jpg" height="2279" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>Part 1</span></th><th class="txxr-borders" colspan="3"><span>Part 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">600-mg<br>Once-Daily Group<br>(N=25)</th><th class="xxxx-borders">300-mg<br>Twice-Daily Group<br>(N=31)</th><th class="xxxx-borders">Placebo<br>Group<br>(N=30)</th><th class="xxxx-borders">300-mg<br>Once-Daily Group<br>(N=15)</th><th class="xxxx-borders">200-mg<br>Twice-Daily Group<br>(N=11)</th><th class="xxxr-borders">Placebo<br>Group<br>(N=12)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">AUC for the mean RSV viral load by RT-qPCR — hr×log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">204.0±173.5</td><td class="xxxx-borders shading">217.7±217.6</td><td class="xxxx-borders shading">790.2±408.8</td><td class="xxxx-borders shading">173.9±194.8</td><td class="xxxx-borders shading">196.2±124.1</td><td class="xxxr-borders shading">879.0±325.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Standard error</td><td class="xxxx-borders">34.7</td><td class="xxxx-borders">39.1</td><td class="xxxx-borders">74.6</td><td class="xxxx-borders">50.3</td><td class="xxxx-borders">37.4</td><td class="xxxr-borders">94.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference from placebo</td><td class="xxxx-borders shading">−588.1</td><td class="xxxx-borders shading">−564.6</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−716.1</td><td class="xxxx-borders shading">−736.2</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−719.8 to −456.4</td><td class="xxxx-borders">−689.2 to −440.0</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−879.9 to −552.2</td><td class="xxxx-borders">−916.4 to −556.1</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">P value</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Least-squares mean difference between EDP-938 groups</td><td class="xxxx-borders">−23.5</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">20.2</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−154.3 to 107.4</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−150.1 to 190.4</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">P value</td><td class="xxxx-borders">0.70</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.80</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">AUC for the mean total symptom score — hr×score</td><td class="xxxx-borders shading">124.5±115.6</td><td class="xxxx-borders shading">181.8±248.4</td><td class="xxxx-borders shading">478.8±422.3</td><td class="xxxx-borders shading">99.3±180.1</td><td class="xxxx-borders shading">89.6±167.7</td><td class="xxxr-borders shading">432.2±342.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Standard error</td><td class="xxxx-borders">23.1</td><td class="xxxx-borders">44.6</td><td class="xxxx-borders">77.1</td><td class="xxxx-borders">46.5</td><td class="xxxx-borders">50.6</td><td class="xxxr-borders">98.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference from placebo</td><td class="xxxx-borders shading">−355.9</td><td class="xxxx-borders shading">−326.6</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−314.0</td><td class="xxxx-borders shading">−312.7</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−506.1 to −205.7</td><td class="xxxx-borders">−469.7 to −183.6</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−494.3 to −133.7</td><td class="xxxx-borders">−508.1 to −117.4</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference between EDP-938 groups</td><td class="xxxx-borders shading">−29.3</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−1.3</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−179.2 to 120.7</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−185.5 to 183.0</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Mean total weight of nasal mucus — g</td><td class="xxxx-borders shading">13.0±13.0</td><td class="xxxx-borders shading">7.4±11.1</td><td class="xxxx-borders shading">33.4±37.8</td><td class="xxxx-borders shading">3.0±4.4</td><td class="xxxx-borders shading">4.7±6.0</td><td class="xxxr-borders shading">22.4±20.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Standard error</td><td class="xxxx-borders">2.6</td><td class="xxxx-borders">2.0</td><td class="xxxx-borders">6.9</td><td class="xxxx-borders">1.1</td><td class="xxxx-borders">1.8</td><td class="xxxr-borders">5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference from placebo</td><td class="xxxx-borders shading">−24.1</td><td class="xxxx-borders shading">−26.0</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−18.1</td><td class="xxxx-borders shading">−19.3</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−36.6 to −11.6</td><td class="xxxx-borders">−37.7 to −14.2</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−27.2 to −9.1</td><td class="xxxx-borders">−29.1 to −9.6</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference between EDP-938 groups</td><td class="xxxx-borders shading">1.9</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">1.2</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−10.6 to 14.3</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−8.3 to 10.7</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">AUC for the mean RSV viral load by CBI assay — hr×log<sub>10</sub> PFU/ml</td><td class="xxxx-borders shading">34.1±63.6</td><td class="xxxx-borders shading">35.9±78.0</td><td class="xxxx-borders shading">185.6±161.7</td><td class="xxxx-borders shading">23.7±81.8</td><td class="xxxx-borders shading">26.1±39.1</td><td class="xxxr-borders shading">244.0±138.01</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Standard error</td><td class="xxxx-borders">12.7</td><td class="xxxx-borders">14.0</td><td class="xxxx-borders">29.5</td><td class="xxxx-borders">21.1</td><td class="xxxx-borders">11.8</td><td class="xxxr-borders">39.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference from placebo</td><td class="xxxx-borders shading">−153.1</td><td class="xxxx-borders shading">−143.7</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−207.6</td><td class="xxxx-borders shading">−209.1</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−208.6 to −97.7</td><td class="xxxx-borders">−196.2 to −91.1</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−281.7 to −133.6</td><td class="xxxx-borders">−288.0 to −130.1</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference between EDP-938 groups</td><td class="xxxx-borders shading">−9.45</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">1.4</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">95% CI</td><td class="xbxx-borders">−64.7 to 45.7</td><td class="xbxx-borders">—</td><td class="xbxx-borders">—</td><td class="xbxx-borders">−73.2 to 76.1</td><td class="xbxx-borders">—</td><td class="xbxr-borders">—</td></tr></tbody></table></div><figcaption><div class="caption">Efficacy Results in Trial Parts 1 and 2 (ITT–Infected Analysis Population).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Plus–minus values are means ±SD. The least-squares mean differences in the treatment effect and the 95% confidence intervals (CIs) were obtained from fitting an analysis-of-covariance model to the end point with the trial group as a main effect and the baseline value of the end-point measure as a covariate. The data were normally distributed, and arithmetic means are presented. The least-squares mean difference between EDP-938 groups was calculated as the value in the once-daily EDP-938 group minus the value in the twice-daily EDP-938 group. AUC denotes area under the curve, CBI cell-based infectivity, PFU plaque-forming unit, and RT-qPCR reverse-transcriptase–quantitative polymerase chain reaction.</div></div></div></figcaption></figure></div><div role="paragraph">The clinical symptoms of RSV followed a pattern similar to that of the viral load: the AUC for the mean total symptom score, expressed as hours×score (the key secondary end point), was 124.5 in the 600-mg once-daily group, 181.8 in the 300-mg twice-daily group, and 478.8 in the placebo group (<a href="#t2">Table 2</a>). The mean total symptom score decreased more quickly in the EDP-938 groups than in the placebo group (<a href="#f1">Figure 1</a>). The 95% confidence intervals for the difference from placebo were negative, indicating that the AUC values for the total symptom score in the placebo group were higher.</div><div role="paragraph">In part 2, the results regarding the AUC for the mean RSV viral load followed a pattern similar to that in part 1, with lower values in the EDP-938 groups than in the placebo group (173.9 in the 300-mg once-daily group, 196.2 in the 200-mg twice-daily group, and 879.0 in the placebo group) (<a href="#t2">Table 2</a> and <a href="#f1">Figure 1</a>). Marked attenuation of clinical symptoms was also observed; the AUC for the mean total symptom score was 99.3 in the 300-mg once-daily group, 89.6 in the 200-mg twice-daily group, and 432.2 in the placebo group (<a href="#t2">Table 2</a> and <a href="#f1">Figure 1</a>).</div><div role="paragraph">In both parts of the trial, mucus production was more than 70% lower in each EDP-938 group than in the placebo group (<a href="#t2">Table 2</a> and <a href="#f1">Figure 1</a>). In addition, in both trial parts, the RSV viral load measured by cell-based infectivity assay was also lower in the EDP-938 groups than in the placebo group (<a href="#t2">Table 2</a> and <a href="#f1">Figure 1</a>), a result consistent with the findings for RSV viral load measured by RT-qPCR assay.</div></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph">In part 1 of the trial, 29 adverse events occurred among 20 participants in the 600-mg once-daily group, 30 occurred among 21 participants in the 300-mg twice-daily group, and 41 occurred among 21 participants in the placebo group. Adverse events that were more common in one or both EDP-938 groups than in the placebo group included headache (in 4 participants in the 600-mg once-daily group, 1 in the 300-mg twice-daily group, and 3 in the placebo group), dizziness (in 4, 0, and 1, respectively), and diarrhea (in 3, 3, and 0, respectively). All adverse events that occurred in the EDP-938 groups were mild except for a single event of moderate dyspepsia. Adverse events possibly related to EDP-938, as determined by the principal investigator, occurred in 4 participants in the 600-mg once-daily group and 10 participants in the 300-mg twice-daily group (<a href="#t3">Table 3</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t3.jpg"><img src="/cms/10.1056/NEJMoa2108903/asset/913997e5-cd88-4c03-8c54-47e6902528a3/assets/images/large/nejmoa2108903_t3.jpg" height="2389" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="3"><span>Part 1</span></th><th class="txxr-borders" colspan="3"><span>Part 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">600-mg<br>Once-Daily Group<br>(N=38)</th><th class="xxxx-borders">300-mg<br>Twice-Daily Group<br>(N=38)</th><th class="xxxx-borders">Placebo<br>Group<br>(N=38)</th><th class="xxxx-borders">300-mg<br>Once-Daily Group<br>(N=21)</th><th class="xxxx-borders">200-mg<br>Twice-Daily Group<br>(N=21)</th><th class="xxxr-borders">Placebo<br>Group<br>(N=21)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse events — no.</td><td class="xxxx-borders shading">29</td><td class="xxxx-borders shading">30</td><td class="xxxx-borders shading">41</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">19</td><td class="xxxr-borders shading">14</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants with adverse events — no. (%)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">20 (53)</td><td class="xxxx-borders">21 (55)</td><td class="xxxx-borders">21 (55)</td><td class="xxxx-borders">8 (38)</td><td class="xxxx-borders">10 (48)</td><td class="xxxr-borders">11 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Participants with grade 1 adverse events</td><td class="xxxx-borders shading">20 (53)</td><td class="xxxx-borders shading">20 (53)</td><td class="xxxx-borders shading">18 (47)</td><td class="xxxx-borders shading">7 (33)</td><td class="xxxx-borders shading">10 (48)</td><td class="xxxr-borders shading">9 (43)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Participants with grade 2 adverse events</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participants with ≥1 adverse event possibly related to trial regimen — no. (%)<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">4 (11)</td><td class="xxxx-borders shading">10 (26)</td><td class="xxxx-borders shading">10 (26)</td><td class="xxxx-borders shading">3 (14)</td><td class="xxxx-borders shading">2 (10)</td><td class="xxxr-borders shading">3 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants with ≥1 adverse event possibly related to RSV-A M37b — no. (%)<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">11 (29)</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">2 (10)</td><td class="xxxx-borders">7 (33)</td><td class="xxxr-borders">7 (33)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Participants with the most common adverse events reported — no. (%)<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Increase in alanine aminotransferase level</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Catheter site–related reaction</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Decrease in appetite</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">1 (5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dizziness</td><td class="xxxx-borders shading">4 (11)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (10)</td><td class="xxxr-borders shading">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dyspepsia</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Ear pain</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decrease in forced expiratory volume</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">4 (11)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxr-borders shading">2 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Musculoskeletal chest pain</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (10)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxx-borders shading">3 (14)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rash</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Skin irritation</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">4 (11)</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">2 (10)</td><td class="xxxr-borders">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Viral upper respiratory tract infection</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (10)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (3)</td><td class="xbxx-borders">1 (3)</td><td class="xbxx-borders">1 (5)</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events in Trial Parts 1 and 2 (Safety Analysis Population).<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The safety analysis population included 115 participants in part 1 and 63 participants in part 2. An adverse event was listed if it occurred after the start of the trial regimen (the first oral dose of EDP-938 was administered 12 hours after confirmation of a positive nasal-wash sample by RT-qPCR assay) in 2 or more participants receiving EDP-938 or placebo or both across parts 1 and 2. Safety was assessed throughout the duration of the trial up to follow-up day 31.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Grade 1 adverse events were considered to be those that led to a mild level of discomfort and did not interfere with the performance of regular activities; grade 2 adverse events, those that led to a moderate level of discomfort and considerably interfered with the performance of regular activities; and grade 3 adverse events, those that led to a severe level of discomfort and prevented the performance of regular activities. Grade 2 adverse events that occurred in part 1 included dyspepsia in 1 participant in the 300-mg twice-daily group and hypoacusis (in 1 participant) and headache (in 2 participants) in the placebo group. Grade 2 adverse events that occurred in part 2 included paresthesia at the venipuncture site in 1 participant in the 300-mg once-daily group and increased aspartate aminotransferase level (in 1 participant) and headache (in 1 participant) in the placebo group. There were no adverse events of worse severity than moderate.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">Whether an adverse event was possibly related to a trial regimen or to RSV-A M37b was determined by the principal investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">The most common adverse events were considered to be those that occurred in 3 or more participants.</div></div></div></figcaption></figure></div><div role="paragraph">In part 2 of the trial, 17 adverse events occurred among 8 participants in the 300-mg once-daily group, 19 occurred among 10 participants in the 200-mg twice-daily group, and 14 among 11 participants in the placebo group. Nausea, dizziness, and upper respiratory tract infection occurred in at least 3 participants across the trial groups and were more common in one or both EDP-938 groups than in the placebo group (nausea occurred in 1 participant in the 300-mg once-daily group, 3 in the 200-mg twice-daily group, and 0 in the placebo group; dizziness in 0, 2, and 1, respectively; and upper respiratory tract infection in 1, 2, and 1, respectively). All adverse events that occurred in the EDP-938 groups were mild except for a single event of moderate paresthesia at the venipuncture site. Adverse events possibly related to EDP-938 occurred in 3 participants in the 300-mg once-daily group and in 2 in the 200-mg twice-daily group (<a href="#t3">Table 3</a>).</div><div role="paragraph">In both trial parts, all events resolved during follow-up except for an event of hematoma at a venipuncture site in part 1. No serious adverse events that led to discontinuation of the trial regimen occurred, and no participant was withdrawn from the trial as a result of an adverse event (<a href="#t3">Table 3</a>).</div></section><section id="sec-2-4"><h3>Pharmacokinetics</h3><div role="paragraph">The data regarding the plasma pharmacokinetic measures after the last dose of EDP-938 on day 5 are shown in <a href="#t4">Table 4</a>. EDP-938 was rapidly absorbed; the median EDP-938 T<sub>max</sub> (time to reach the maximum plasma concentration) ranged from 4 to 5 hours across all regimens. Similarly, the geometric mean half-life ranged from 13.7 to 14.5 hours across all regimens and appeared to be independent of dose and frequency of administration. A steady state was reached with the third dose of EDP-938. The geometric mean CL<sub>ss/F</sub> (apparent systemic clearance) and V<sub>ss/F</sub> (volume of distribution at steady state) were also generally similar across all regimens and appeared to be independent of dose and frequency of administration.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 4</div><nav><a href="#t4" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t4.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t4" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t4.jpg"><img src="/cms/10.1056/NEJMoa2108903/asset/5aa564d4-d635-424b-9008-0ce2ed67e26e/assets/images/large/nejmoa2108903_t4.jpg" height="2725" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Measure</th><th class="txxx-borders" colspan="2"><span>Part 1<a href="#t4fn2" role="doc-noteref">†</a></span></th><th class="txxr-borders" colspan="2"><span>Part 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">600-mg<br>Once-Daily Group<br>(N=38)</th><th class="xxxx-borders">300-mg<br>Twice-Daily Group<br>(N=35)</th><th class="xxxx-borders">300-mg<br>Once-Daily Group<br>(N=21)</th><th class="xxxr-borders">200-mg<br>Twice-Daily Group<br>(N=20)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">C<sub>max</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — ng/ml</td><td class="xxxx-borders">1740</td><td class="xxxx-borders">1480</td><td class="xxxx-borders">1010</td><td class="xxxr-borders">901</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">52.8</td><td class="xxxx-borders shading">33.4</td><td class="xxxx-borders shading">15.9</td><td class="xxxr-borders shading">27.9</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Median T<sub>max</sub> — hr</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">4.52</td><td class="xxxx-borders shading">4.10</td><td class="xxxx-borders shading">4.98</td><td class="xxxr-borders shading">4.04</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Min–max</td><td class="xxxx-borders">1.9–17.0</td><td class="xxxx-borders">0.0–10.1</td><td class="xxxx-borders">1.0–15.9</td><td class="xxxr-borders">0.0–10.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Half-life</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — hr</td><td class="xxxx-borders">14.5</td><td class="xxxx-borders">13.8</td><td class="xxxx-borders">14.5</td><td class="xxxr-borders">13.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">25.4</td><td class="xxxx-borders shading">27.4</td><td class="xxxx-borders shading">31.3</td><td class="xxxr-borders shading">23.5</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">CL<sub>ss/F</sub></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean — liters/hr</td><td class="xxxx-borders shading">26.9</td><td class="xxxx-borders shading">24.1</td><td class="xxxx-borders shading">21.3</td><td class="xxxr-borders shading">25.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">%GCV</td><td class="xxxx-borders">44.8</td><td class="xxxx-borders">28.4</td><td class="xxxx-borders">17.6</td><td class="xxxr-borders">23.9</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">V<sub>ss/F</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — liters</td><td class="xxxx-borders">560</td><td class="xxxx-borders">476</td><td class="xxxx-borders">442</td><td class="xxxr-borders">491</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">42.8</td><td class="xxxx-borders shading">23.1</td><td class="xxxx-borders shading">24.1</td><td class="xxxr-borders shading">28.8</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">C<sub>12</sub></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean — ng/ml</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">822</td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">525</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">%GCV</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">35.2</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">30.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">C<sub>24</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — ng/ml</td><td class="xxxx-borders">491</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">287</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">46.9</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">31.6</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">AUC<sub>0–last</sub></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean — hr×ng/ml</td><td class="xxxx-borders shading">32,000</td><td class="xxxx-borders shading">27,300</td><td class="xxxx-borders shading">20,500</td><td class="xxxr-borders shading">17,800</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">%GCV</td><td class="xxxx-borders">52.9</td><td class="xxxx-borders">40.8</td><td class="xxxx-borders">32.1</td><td class="xxxr-borders">29.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">T<sub>last</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — hr</td><td class="xxxx-borders">76.9</td><td class="xxxx-borders">66.1</td><td class="xxxx-borders">76.6</td><td class="xxxr-borders">65.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">11.0</td><td class="xxxx-borders shading">11.3</td><td class="xxxx-borders shading">13.7</td><td class="xxxr-borders shading">12.1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">AUC<sub>0–12</sub></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean — hr×ng/ml</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">12,600</td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">8030</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">%GCV</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">29.2</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">24.9</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">AUC<sub>0–24</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — hr×ng/ml</td><td class="xxxx-borders">22,700</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">14,100</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xbxx-borders shading">45.7</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">18.4</td><td class="xbxr-borders shading">NA</td></tr></tbody></table></div><figcaption><div class="caption">Plasma Pharmacokinetic Measures of EDP-938 after Administration of the Last Dose in Trial Parts 1 and 2 (PK Analysis Population).<a href="#t4fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t4fn1" role="paragraph">Values are presented as the geometric mean, with the percentage of geometric coefficient of variation (%GCV), for all measures except T<sub>max</sub>, for which the values are presented as the median, with the minimum–maximum (min–max) range. The %GCV was calculated as the square root of the back-transformed standard deviation of plasma concentration of EDP-938 and is expressed as percentage. AUC<sub>0–12</sub> denotes area under the plasma concentration–time curve (time 0 to 12 hours), AUC<sub>0–24</sub> area under the plasma concentration–time curve (time 0 to 24 hours), AUC<sub>0–last</sub> area under the plasma concentration–time curve (time 0 to last quantifiable concentration), C<sub>12</sub> plasma concentration at 12 hours, C<sub>24</sub> plasma concentration at 24 hours, C<sub>max</sub> maximum observed plasma concentration, CL<sub>ss/F</sub> apparent systemic clearance, NA not applicable, T<sub>last</sub> time to the first measurable nonzero concentration, T<sub>max</sub> time to reach the maximum plasma concentration, and V<sub>ss/F</sub> volume of distribution at steady state.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t4fn2" role="paragraph">In part 1, the plasma concentrations were below the limit of quantification in 1 participant in the 300-mg twice-daily group.</div></div></div></figcaption></figure></div><div role="paragraph">On day 5, after completion of the assigned regimen, the geometric mean plasma concentration at 24 hours was 287 ng per milliliter in the 300-mg once-daily group and 491 ng per milliliter in the 600-mg once-daily group, whereas the geometric mean plasma concentration at 12 hours was 525 ng per milliliter in the 200-mg twice-daily group and 822 ng per milliliter in the 300-mg twice-daily group. These concentrations at 12 and 24 hours are approximately 14.5 to 40 times as high as the in vitro EC<sub>90</sub> (the effective concentration at which there is a 90% decrease in viral replication) for EDP-938 against RSV-A M37b.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">This trial was designed in two parts. Part 1 was powered for both viral load and total symptom score and represented the main proof-of-concept portion of the trial. Part 2 was conducted after the data analysis in part 1 and was powered for viral load. The main purpose of part 2 was to evaluate lower doses in an attempt to identify a minimally effective dose in the human virus challenge model.</div><div role="paragraph">The results of parts 1 and 2 show that EDP-938 administered orally for 5 days reduced both the RSV viral load and clinical symptoms in healthy participants challenged with a clinical RSV strain. The adverse events were generally mild and resolved. A minimally effective dose was not identified, and there was no apparent dose–response relationship regarding efficacy measures across EDP-938 regimens.</div><div role="paragraph">The results of the plasma pharmacokinetic measures of EDP-938 were generally similar to those observed in the first-in-human study.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-3" href-manipulated="true" aria-label="Reference 11">11</a></sup> EDP-938 was rapidly absorbed and had a half-life that supports once- or twice-daily dosing. After 5 days of dosing, the trough plasma concentration was approximately 14.5 to 40 times as high as the in vitro EC<sub>90</sub> of RSV-A M37b across dosing groups in parts 1 and 2.</div><div role="paragraph">The healthy human virus challenge model provided an interrogation of the clinical safety and efficacy of EDP-938 before the conduct of studies in at-risk populations. A potential limitation of the challenge model is that RSV infection can be diagnosed and treated early. By comparison, in the clinic, RSV infection may manifest later in the disease course with more severe, advanced infection (i.e., lower-airway disease). It has been suggested that in persons at risk, such later manifestations could attenuate the clinical efficacy of a new treatment, particularly that of agents that block viral entry, such as RSV fusion inhibitors.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> In addition, it has been suggested that for an intervention against RSV, a therapeutic window for symptom duration may exist, analogous to the window observed in approved treatments of influenza.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16 r17" id="body-ref-r17" href-manipulated="true">15-17</a></sup> Because EDP-938 functions through a different mechanism of action (i.e., inhibition of the viral N protein, which is effective at the stages of entry into human cells and after entry), it is possible that the window for an intervention with EDP-938 may be longer. Intervention with EDP-938 after only a short symptom window of up to 48 hours in adults with upper respiratory tract infection is currently being evaluated in an ongoing clinical study (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT04196101" target="_blank">NCT04196101</a>).</div><div role="paragraph">In this human virus challenge trial, all EDP-938 regimens were shown to be superior to placebo with regard to the lowering of viral load, total symptom scores, and mucus weight. The safety profiles of the four EDP-938 regimens studied were similar to the profile of placebo, with no apparent dose–response relationship regarding efficacy measures. The EDP-938 trough plasma concentrations were approximately 14.5 to 40 times as high as the in vitro EC<sub>90</sub> of RSV-A M37b across dosing groups. These findings support the exploration of EDP-938 activity in populations with RSV infection, including those most at risk for severe RSV infection.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank Eoin Coakley, Kajal Larson, Ty McClure, and Kai Lin (Enanta Pharmaceuticals) for their dedication and contributions to an earlier version of the manuscript and Merel Hazewindus (Venn Life Science) for assistance in writing the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2108903_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2108903/suppl_file/nejmoa2108903_protocol.pdf" download="nejmoa2108903_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2108903_protocol.pdf" data-doi="10.1056/NEJMoa2108903">Download</a></li><li>4.63 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2108903_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2108903/suppl_file/nejmoa2108903_appendix.pdf" download="nejmoa2108903_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2108903_appendix.pdf" data-doi="10.1056/NEJMoa2108903">Download</a></li><li>1.15 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2108903_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2108903/suppl_file/nejmoa2108903_disclosures.pdf" download="nejmoa2108903_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2108903_disclosures.pdf" data-doi="10.1056/NEJMoa2108903">Download</a></li><li>319.99 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2108903_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2108903/suppl_file/nejmoa2108903_data-sharing.pdf" download="nejmoa2108903_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2108903_data-sharing.pdf" data-doi="10.1056/NEJMoa2108903">Download</a></li><li>70.12 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Meissner HC. Viral bronchiolitis in children. <em>N Engl J Med</em> 2016;374:62-72.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2108903&amp;key=10.1056%2FNEJMra1413456&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26735994/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000367580500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Viral+bronchiolitis+in+children.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=62-72&amp;doi=10.1056%2FNEJMra1413456&amp;pmid=26735994" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Tong S, Amand C, Kieffer A, Kyaw MH. Incidence of respiratory syncytial virus related health care utilization in the United States. <em>J Glob Health</em> 2020;10:020422-020422.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7189/jogh.10.020422" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33110581/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000612476300134" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence+of+respiratory+syncytial+virus+related+health+care+utilization+in+the+United+States.&amp;publication_year=2020&amp;journal=J+Glob+Health&amp;pages=020422-020422&amp;doi=10.7189%2Fjogh.10.020422&amp;pmid=33110581" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] older adults, and immunocompromised adults. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] 80% of RSV cases across all age groups. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory syncytial virus seasonality — United States, 2014–2017. <em>MMWR Morb Mortal Wkly Rep</em> 2018;67:71-76.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm6702a4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29346336/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000422763400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Respiratory+syncytial+virus+seasonality+%E2%80%94+United+States%2C+2014%E2%80%932017.&amp;publication_year=2018&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=71-76&amp;doi=10.15585%2Fmmwr.mm6702a4&amp;pmid=29346336" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Centers for Disease Control and Prevention. Respiratory syncytial virus-associated mortality (RSV-associated mortality): 2019 case definition. 2021 (<a href="https://ndc.services.cdc.gov/case-definitions/respiratory-syncytial-virus-associated-mortality-2019/">https://ndc.services.cdc.gov/case-definitions/respiratory-syncytial-virus-associated-mortality-2019/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Respiratory+syncytial+virus-associated+mortality+%28RSV-associated+mortality%29%3A+2019+case+definition.&amp;publication_year=2021" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] older adults, and immunocompromised adults. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with RSV infections occur annually. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] among children younger than 5 years of age. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. <em>Lancet</em> 2017;390:946-958.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)30938-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28689664/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408746300024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global%2C+regional%2C+and+national+disease+burden+estimates+of+acute+lower+respiratory+infections+due+to+respiratory+syncytial+virus+in+young+children+in+2015%3A+a+systematic+review+and+modelling+study.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=946-958&amp;doi=10.1016%2FS0140-6736%2817%2930938-8&amp;pmid=28689664" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. <em>Cochrane Database Syst Rev</em> 2007;1:CD000181-CD000181.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17253446/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000243747900114" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ribavirin+for+respiratory+syncytial+virus+infection+of+the+lower+respiratory+tract+in+infants+and+young+children.&amp;publication_year=2007&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD000181-CD000181&amp;pmid=17253446" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Lee N, Lui GCY, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. <em>Clin Infect Dis</em> 2013;57:1069-1077.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/cit471" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23876395/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325168100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High+morbidity+and+mortality+in+adults+hospitalized+for+respiratory+syncytial+virus+infections.&amp;publication_year=2013&amp;journal=Clin+Infect+Dis&amp;pages=1069-1077&amp;doi=10.1093%2Fcid%2Fcit471&amp;pmid=23876395" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Bollani L, Baraldi E, Chirico G, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). <em>Ital J Pediatr</em> 2015;41:97-97.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13052-015-0203-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26670908/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366457700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revised+recommendations+concerning+palivizumab+prophylaxis+for+respiratory+syncytial+virus+%28RSV%29.&amp;publication_year=2015&amp;journal=Ital+J+Pediatr&amp;pages=97-97&amp;doi=10.1186%2Fs13052-015-0203-x&amp;pmid=26670908" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Challa S, Scott AD, Yuzhakov O, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. <em>Antimicrob Agents Chemother</em> 2015;59:1080-1087.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.04119-14" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25451060/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348610000040" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanism+of+action+for+respiratory+syncytial+virus+inhibitor+RSV604.&amp;publication_year=2015&amp;journal=Antimicrob+Agents+Chemother&amp;pages=1080-1087&amp;doi=10.1128%2FAAC.04119-14&amp;pmid=25451060" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Rhodin MHJ, McAllister NV, Castillo J, et al. EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. <em>PLoS Pathog</em> 2021;17(3):e1009428-e1009428.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.ppat.1009428" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33720995/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000629666900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EDP-938%2C+a+novel+nucleoprotein+inhibitor+of+respiratory+syncytial+virus%2C+demonstrates+potent+antiviral+activities+in+vitro+and+in+a+non-human+primate+model.&amp;publication_year=2021&amp;journal=PLoS+Pathog&amp;pages=e1009428-e1009428&amp;doi=10.1371%2Fjournal.ppat.1009428&amp;pmid=33720995" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the viral nucleoprotein (N protein). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is distinct from RSV fusion inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] as compared with vehicle control. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Adda N, Dickerson D, Sanderson K, Ahmad A. EDP-938, a novel, non-fusion replication inhibitor of respiratory syncytial virus: preliminary results of a phase 1 study in healthy subjects (HS). Presented at the 11th International Respiratory Syncytial Virus Symposium, Asheville, NC, October 31–November 4, 2018. P104.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Adda+N%2C+Dickerson+D%2C+Sanderson+K%2C+Ahmad+A.+EDP-938%2C+a+novel%2C+non-fusion+replication+inhibitor+of+respiratory+syncytial+virus%3A+preliminary+results+of+a+phase+1+study+in+healthy+subjects+%28HS%29.+Presented+at+the+11th+International+Respiratory+Syncytial+Virus+Symposium%2C+Asheville%2C+NC%2C+October+31%E2%80%93November+4%2C+2018.+P104." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 18 hours across multiple dosing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for 7 days without evident safety concerns. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] those observed in the first-in-human study. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Kelly G, Laxton C, Garelnabi M, et al. Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a respiratory syncytial virus human viral challenge model (hVCM). <em>J Virol Methods</em> 2015;224:83-90.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jviromet.2015.08.019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26335961/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000361864000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+qualitative+integrative+cycler+PCR+%28qicPCR%29+to+identify+optimal+therapeutic+dosing+time-points+in+a+respiratory+syncytial+virus+human+viral+challenge+model+%28hVCM%29.&amp;publication_year=2015&amp;journal=J+Virol+Methods&amp;pages=83-90&amp;doi=10.1016%2Fj.jviromet.2015.08.019&amp;pmid=26335961" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. <em>BMJ</em> 1990;300:230-235.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.300.6719.230" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2106931/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1990CL02400023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analysis+of+serial+measurements+in+medical+research.&amp;publication_year=1990&amp;journal=BMJ&amp;pages=230-235&amp;doi=10.1136%2Fbmj.300.6719.230&amp;pmid=2106931" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Marty FM, Chemaly RF, Mullane KM, et al. A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract. <em>Clin Infect Dis</em> 2020;71:2787-2795.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciz1167" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31915807/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000607829500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+2b%2C+randomized%2C+double-blind%2C+placebo-controlled+multicenter+study+evaluating+antiviral+effects%2C+pharmacokinetics%2C+safety%2C+and+tolerability+of+presatovir+in+hematopoietic+cell+transplant+recipients+with+respiratory+syncytial+virus+infection+of+the+lower+respiratory+tract.&amp;publication_year=2020&amp;journal=Clin+Infect+Dis&amp;pages=2787-2795&amp;doi=10.1093%2Fcid%2Fciz1167&amp;pmid=31915807" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Ison MG. Optimum timing of oseltamivir: lessons from Bangladesh. <em>Lancet Infect Dis</em> 2014;14:88-89.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(13)70287-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24268592/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330420400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Optimum+timing+of+oseltamivir%3A+lessons+from+Bangladesh.&amp;publication_year=2014&amp;journal=Lancet+Infect+Dis&amp;pages=88-89&amp;doi=10.1016%2FS1473-3099%2813%2970287-1&amp;pmid=24268592" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. <em>Lancet Infect Dis</em> 2014;14:109-118.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(13)70267-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24268590/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330420400024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+oseltamivir+treatment+started+within+5+days+of+symptom+onset+to+reduce+influenza+illness+duration+and+virus+shedding+in+an+urban+setting+in+Bangladesh%3A+a+randomised+placebo-controlled+trial.&amp;publication_year=2014&amp;journal=Lancet+Infect+Dis&amp;pages=109-118&amp;doi=10.1016%2FS1473-3099%2813%2970267-6&amp;pmid=24268590" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">McLean HQ, Belongia EA, Kieke BA, Meece JK, Fry AM. Impact of late oseltamivir treatment on influenza symptoms in the outpatient setting: results of a randomized trial. <em>Open Forum Infect Dis</em> 2015;2(3):ofv100.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/ofid/ofv100" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26258157/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365786500026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+late+oseltamivir+treatment+on+influenza+symptoms+in+the+outpatient+setting%3A+results+of+a+randomized+trial.&amp;publication_year=2015&amp;journal=Open+Forum+Infect+Dis&amp;doi=10.1093%2Fofid%2Fofv100&amp;pmid=26258157" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/386/7"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">386</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">7</span></span> • <span property="datePublished">February 17, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">655</span>-<span property="pageEnd">666</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2108903" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2108903?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: February 16, 2022</div><div><b class="core-label">Published in issue</b>: February 17, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/infectious-disease-general" alt="View article keyword Infectious Disease General" data-interactiontype="article_recirculation_click">Infectious Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/vaccines" alt="View article keyword Vaccines" data-interactiontype="article_recirculation_click">Vaccines</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/viral-infections" alt="View article keyword Viral Infections" data-interactiontype="article_recirculation_click">Viral Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Alaa</span> <span property="familyName">Ahmad</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kingsley</span> <span property="familyName">Eze</span>, <span property="honorificSuffix">B.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nicolas</span> <span property="familyName">Noulin</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Veronika</span> <span property="familyName">Horvathova</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bryan</span> <span property="familyName">Murray</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mark</span> <span property="familyName">Baillet</span>, <span property="honorificSuffix">B.Sc., C.Stat.</span></span>, <span property="author" typeof="Person"><span property="givenName">Laura</span> <span property="familyName">Grey</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Julie</span> <span property="familyName">Mori</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Nathalie</span> <span property="familyName">Adda</span>, <span property="honorificSuffix">M.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Enanta Pharmaceuticals, Watertown, MA (A.A., N.A.); hVIVO, London (K.E., N.N., J.M.), Boyd Consultants, Crew (B.M.), BJM Pharma, St. Neots (B.M.), and S-Cubed Biometrics, Abingdon (M.B., L.G.) — all in the United Kingdom; and Linical, Frankfurt, Germany (V.H.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Ahmad can be contacted at <a href="mailto:aahmad@enanta.com">aahmad@enanta.com</a> or at Enanta Pharmaceuticals, 400 Talcott Ave., Watertown, MA 02472.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">49</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2108903" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="57e40b16-580a-fc3c-5e1e-4228bfc5d372"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=123186638" style="display:inline-block;">
                <img alt="Article has an altmetric score of 82" src="https://badges.altmetric.com/?size=320&amp;score=82&amp;types=mttttttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=123186638">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_57e40b16-580a-fc3c-5e1e-4228bfc5d372" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=123186638&amp;tab=news">
          Picked up by <b>7</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=123186638&amp;tab=twitter">
          Posted by <b>48</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=123186638&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>83</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6bf7a523b1aed-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2108903"> <input type="hidden" name="downloadFileName" value="csp_386_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2108903%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-7" data-lazyload="false" data-total="49" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Prosenjit Kundu, </li><li class="list-inline-item cited-by__entry__author">Mark Quinn, </li><li class="list-inline-item cited-by__entry__author">Elaine Thomas, </li><li class="list-inline-item cited-by__entry__author">Jared C. Christensen, </li><li class="list-inline-item cited-by__entry__author">Sima S. Toussi, </li><li class="list-inline-item cited-by__entry__author">Negar Niki Alami, </li><li class="list-inline-item cited-by__entry__author">Anindita Banerjee, </li></ul><span class="cited-by__entry__title">Role of human infection challenge studies (HICs) in drug development for respiratory syncytial virus (RSV): systematic review and meta-analysis, </span><span class="cited-by__entry__series-title">eBioMedicine, </span><span class="cited-by__entry__volume"><strong>117</strong>, </span><span class="cited-by__entry__page-range">(105765), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ebiom.2025.105765" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ebiom.2025.105765</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ebiom.2025.105765" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jay H. Kalin, </li><li class="list-inline-item cited-by__entry__author">Yanting Yin, </li><li class="list-inline-item cited-by__entry__author">Minh T. Tran, </li><li class="list-inline-item cited-by__entry__author">Madison Piassek, </li><li class="list-inline-item cited-by__entry__author">Amy Fung, </li><li class="list-inline-item cited-by__entry__author">Sandrine Grosse, </li><li class="list-inline-item cited-by__entry__author">Edgar Jacoby, </li><li class="list-inline-item cited-by__entry__author">Anusarka Bhaumik, </li><li class="list-inline-item cited-by__entry__author">Suraj Adhikary, </li><li class="list-inline-item cited-by__entry__author">Robyn Miller, </li><li class="list-inline-item cited-by__entry__author">Cynthia Lemmens, </li><li class="list-inline-item cited-by__entry__author">Ferdinand H. Lutter, </li><li class="list-inline-item cited-by__entry__author">Serge Pieters, </li><li class="list-inline-item cited-by__entry__author">Ludwig Cooymans, </li><li class="list-inline-item cited-by__entry__author">Geert Rombouts, </li><li class="list-inline-item cited-by__entry__author">Daniel Oehlrich, </li><li class="list-inline-item cited-by__entry__author">Sonia Tomaso, </li><li class="list-inline-item cited-by__entry__author">Kate Lozada, </li><li class="list-inline-item cited-by__entry__author">Miguel Osorio Garcia, </li><li class="list-inline-item cited-by__entry__author">Brandon Anson, </li><li class="list-inline-item cited-by__entry__author">Suzanne De Bruyn, </li><li class="list-inline-item cited-by__entry__author">Constance Smith-Monroy, </li><li class="list-inline-item cited-by__entry__author">Jean-Marc Neefs, </li><li class="list-inline-item cited-by__entry__author">Nádia Conceição-Neto, </li><li class="list-inline-item cited-by__entry__author">Bart Stoops, </li><li class="list-inline-item cited-by__entry__author">Herman van Vlijmen, </li><li class="list-inline-item cited-by__entry__author">Aaron Patrick, </li><li class="list-inline-item cited-by__entry__author">Xiaodi Yu, </li><li class="list-inline-item cited-by__entry__author">Victoria Wong, </li><li class="list-inline-item cited-by__entry__author">Daniel Krosky, </li><li class="list-inline-item cited-by__entry__author">Pravien Abeywickrema, </li><li class="list-inline-item cited-by__entry__author">Stephen Mason, </li><li class="list-inline-item cited-by__entry__author">Zhinan Jin, </li><li class="list-inline-item cited-by__entry__author">Tim H. M. Jonckers, </li><li class="list-inline-item cited-by__entry__author">Sujata Sharma, </li></ul><span class="cited-by__entry__title">Discovery of a non-nucleoside inhibitor that binds to a novel site in the palm domain of the respiratory syncytial virus RNA-dependent RNA polymerase, </span><span class="cited-by__entry__series-title">Journal of Virology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1128/jvi.00178-25" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1128/jvi.00178-25</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1128/jvi.00178-25" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"></ul><span class="cited-by__entry__title">Presatovir: A Once‐daily Oral Respiratory Syncytial Virus Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus Infection in Adults and Infants, </span><span class="cited-by__entry__series-title">Trends in Antiviral Drug Development, </span><span class="cited-by__entry__page-range">(309-332), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/9783527845088.ch09" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/9783527845088.ch09</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/9783527845088.ch09" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mickie H. Cheng, </li><li class="list-inline-item cited-by__entry__author">Alex J. Mann, </li><li class="list-inline-item cited-by__entry__author">Brian M. Maas, </li><li class="list-inline-item cited-by__entry__author">Tian Zhao, </li><li class="list-inline-item cited-by__entry__author">Melissa Bevan, </li><li class="list-inline-item cited-by__entry__author">Andrea K. Schaeffer, </li><li class="list-inline-item cited-by__entry__author">Laura E. Liao, </li><li class="list-inline-item cited-by__entry__author">Andrew P. Catchpole, </li><li class="list-inline-item cited-by__entry__author">David W. Hilbert, </li><li class="list-inline-item cited-by__entry__author">S. Aubrey Stoch, </li><li class="list-inline-item cited-by__entry__author">Carisa S. De Anda, </li></ul><span class="cited-by__entry__title">A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus, </span><span class="cited-by__entry__series-title">Pulmonary Therapy, </span><span class="cited-by__entry__volume"><strong>11</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(285-304), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s41030-025-00289-z" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s41030-025-00289-z</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s41030-025-00289-z" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ziheng Feng, </li><li class="list-inline-item cited-by__entry__author">Zhengde Xie, </li><li class="list-inline-item cited-by__entry__author">Lili Xu, </li></ul><span class="cited-by__entry__title">Current antiviral therapies and promising drug candidates against respiratory syncytial virus infection, </span><span class="cited-by__entry__series-title">Virologica Sinica, </span><span class="cited-by__entry__volume"><strong>40</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(147-156), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.virs.2025.01.003" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.virs.2025.01.003</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.virs.2025.01.003" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sean M. Carney, </li><li class="list-inline-item cited-by__entry__author">Sandrine Grosse, </li><li class="list-inline-item cited-by__entry__author">Yanting Yin, </li><li class="list-inline-item cited-by__entry__author">Minh T. Tran, </li><li class="list-inline-item cited-by__entry__author">Jay H. Kalin, </li><li class="list-inline-item cited-by__entry__author">Edgar Jacoby, </li><li class="list-inline-item cited-by__entry__author">Amy Fung, </li><li class="list-inline-item cited-by__entry__author">Nicholas Simmons, </li><li class="list-inline-item cited-by__entry__author">Xiaoming Xie, </li><li class="list-inline-item cited-by__entry__author">Anusarka Bhaumik, </li><li class="list-inline-item cited-by__entry__author">Rodrigo J. Carbajo, </li><li class="list-inline-item cited-by__entry__author">Madison Piassek, </li><li class="list-inline-item cited-by__entry__author">Robyn Miller, </li><li class="list-inline-item cited-by__entry__author">Lili Hu, </li><li class="list-inline-item cited-by__entry__author">Cynthia Lemmens, </li><li class="list-inline-item cited-by__entry__author">Ferdinand H. Lutter, </li><li class="list-inline-item cited-by__entry__author">Serge Pieters, </li><li class="list-inline-item cited-by__entry__author">Geert Rombouts, </li><li class="list-inline-item cited-by__entry__author">Irene Vetrano, </li><li class="list-inline-item cited-by__entry__author">Daniel Oehlrich, </li><li class="list-inline-item cited-by__entry__author">Sonia Tomaso, </li><li class="list-inline-item cited-by__entry__author">Kate Lozada, </li><li class="list-inline-item cited-by__entry__author">Miguel Osorio Garcia, </li><li class="list-inline-item cited-by__entry__author">Brandon Anson, </li><li class="list-inline-item cited-by__entry__author">Suzanne De Bruyn, </li><li class="list-inline-item cited-by__entry__author">Constance Smith-Monroy, </li><li class="list-inline-item cited-by__entry__author">Jean-Marc Neefs, </li><li class="list-inline-item cited-by__entry__author">Nádia Conceição-Neto, </li><li class="list-inline-item cited-by__entry__author">Bart Kesteleyn, </li><li class="list-inline-item cited-by__entry__author">Roberto Fino, </li><li class="list-inline-item cited-by__entry__author">Bart Stoops, </li><li class="list-inline-item cited-by__entry__author">Herman van Vlijmen, </li><li class="list-inline-item cited-by__entry__author">Aaron N. Patrick, </li><li class="list-inline-item cited-by__entry__author">Xiaodi Yu, </li><li class="list-inline-item cited-by__entry__author">Victoria Wong, </li><li class="list-inline-item cited-by__entry__author">Daniel J. Krosky, </li><li class="list-inline-item cited-by__entry__author">Pravien Abeywickrema, </li><li class="list-inline-item cited-by__entry__author">Rodrigo F. Ortiz-Meoz, </li><li class="list-inline-item cited-by__entry__author">Stephen W. Mason, </li><li class="list-inline-item cited-by__entry__author">Zhinan Jin, </li><li class="list-inline-item cited-by__entry__author">Sujata Sharma, </li><li class="list-inline-item cited-by__entry__author">Tim H. M. Jonckers, </li></ul><span class="cited-by__entry__title">DNA-Encoded Library Screen Identifies Novel Series of Respiratory Syncytial Virus Polymerase Inhibitors, </span><span class="cited-by__entry__series-title">Journal of Medicinal Chemistry, </span><span class="cited-by__entry__volume"><strong>68</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(6407-6430), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1021/acs.jmedchem.4c02906" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1021/acs.jmedchem.4c02906</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1021/acs.jmedchem.4c02906" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Harald Brüssow, </li></ul><span class="cited-by__entry__title">Respiratory syncytial virus: health burden, disease prevention, and treatment—recent progress and lessons learned, </span><span class="cited-by__entry__series-title">microLife, </span><span class="cited-by__entry__volume"><strong>6</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1093/femsml/uqaf003" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1093/femsml/uqaf003</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1093/femsml/uqaf003" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ge Yang, </li><li class="list-inline-item cited-by__entry__author">Guangyu Jiang, </li><li class="list-inline-item cited-by__entry__author">Jiandong Jiang, </li><li class="list-inline-item cited-by__entry__author">Yuhuan Li, </li></ul><span class="cited-by__entry__title">Advances in development of antiviral strategies against respiratory syncytial virus, </span><span class="cited-by__entry__series-title">Acta Pharmaceutica Sinica B, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.apsb.2025.02.015" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.apsb.2025.02.015</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.apsb.2025.02.015" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Emmanuel B. Walter, </li><li class="list-inline-item cited-by__entry__author">Flor M. Munoz, </li></ul><span class="cited-by__entry__title">New Approaches to Respiratory Syncytial Virus Prevention and Treatment, </span><span class="cited-by__entry__series-title">Annual Review of Medicine, </span><span class="cited-by__entry__volume"><strong>76</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(13-28), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1146/annurev-med-061323-073934" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1146/annurev-med-061323-073934</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1146/annurev-med-061323-073934" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michael P. Citron, </li><li class="list-inline-item cited-by__entry__author">Xiaowei Zang, </li><li class="list-inline-item cited-by__entry__author">Andrew Leithead, </li><li class="list-inline-item cited-by__entry__author">Shi Meng, </li><li class="list-inline-item cited-by__entry__author">William A. Rose II, </li><li class="list-inline-item cited-by__entry__author">Edward Murray, </li><li class="list-inline-item cited-by__entry__author">Jane Fontenot, </li><li class="list-inline-item cited-by__entry__author">John P. Bilello, </li><li class="list-inline-item cited-by__entry__author">Douglas C. Beshore, </li><li class="list-inline-item cited-by__entry__author">John A. Howe, </li></ul><span class="cited-by__entry__title">Evaluation of a non-nucleoside inhibitor of the RSV RNA-dependent RNA polymerase in translatable animals models, </span><span class="cited-by__entry__series-title">Journal of Infection, </span><span class="cited-by__entry__volume"><strong>89</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(106325), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1016/j.jinf.2024.106325" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jinf.2024.106325</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jinf.2024.106325" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2108903%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-7" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2108903" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2108903" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2108903.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2108903_f1.jpg"><img src="/cms/10.1056/NEJMoa2108903/asset/65155284-a088-4147-9214-36dbeb3f8404/assets/images/large/nejmoa2108903_f1.jpg" height="3272" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Viral Load, Clinical Symptoms, and Mucus Weight in Trial Parts 1 and 2.</div><div class="notes"><div role="doc-footnote">Shown are the mean (±SE) respiratory syncytial virus loads, total symptom scores, and mucus weight from the time immediately before administration of the first dose until 10 days afterward in the intention-to-treat–infected analysis population, which included the participants who had been inoculated with the respiratory syncytial virus A Memphis 37b strain, had received at least one dose of EDP-938 or placebo, and had confirmed infection. In part 1 of the trial, 115 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a once-daily 600-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 600-mg once-daily group), a 500-mg loading dose of EDP-938 followed by a 300-mg second dose 11 to 13 hours later and then 300 mg of EDP-938 twice daily (the 300-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours. In part 2 of the trial, 63 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a 600-mg loading dose of EDP-938 followed by placebo 11 to 13 hours later and then a once-daily 300-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 300-mg once-daily group), a 400-mg loading dose of EDP-938 followed by a 200-mg second dose 11 to 13 hours later and then 200 mg of EDP-938 twice daily (the 200-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours. The total symptom score is the sum of the scores for all 10 symptoms that were listed in the diary card and assessed by the participants 3 times daily. The score for each symptom ranged from 0 to 3, with higher scores indicating greater severity (additional details are provided in Section 10.7.2.1 of the statistical analysis plan, available with the <a href="#ap1">protocol</a> at NEJM.org). CBI denotes cell-based infectivity, PFU plaque-forming unit, and RT-qPCR reverse-transcriptase–quantitative polymerase chain reaction.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2108903_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2108903/asset/faac943e-e432-48af-b05a-2fa154c7a92a/assets/images/large/nejmoa2108903_t1.jpg" height="1928" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Participants</th><th class="txxx-borders" colspan="4"><span>Part 1<a href="#core-t1fn2" role="doc-noteref">†</a></span></th><th class="txxr-borders" colspan="4"><span>Part 2<a href="#core-t1fn3" role="doc-noteref">‡</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">600-mg<br>Once-Daily Group</th><th class="xxxx-borders">300-mg<br>Twice-Daily Group</th><th class="xxxx-borders">Placebo<br>Group</th><th class="xxxx-borders">Total</th><th class="xxxx-borders">300-mg<br>Once-Daily Group</th><th class="xxxx-borders">200-mg<br>Twice-Daily Group</th><th class="xxxx-borders">Placebo<br>Group</th><th class="xxxr-borders">Total</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Were inoculated — no.</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">38</td><td class="xxxx-borders shading">38</td><td class="xxxx-borders shading">115</td><td class="xxxx-borders shading">21</td><td class="xxxx-borders shading">21</td><td class="xxxx-borders shading">21</td><td class="xxxr-borders shading">63</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Underwent randomization — no.</td><td class="xxxx-borders">39</td><td class="xxxx-borders">38</td><td class="xxxx-borders">38</td><td class="xxxx-borders">115</td><td class="xxxx-borders">21</td><td class="xxxx-borders">21</td><td class="xxxx-borders">21</td><td class="xxxr-borders">63</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Were included in the ITT analysis population — no. (%)</td><td class="xxxx-borders shading">38 (97)</td><td class="xxxx-borders shading">38 (100)</td><td class="xxxx-borders shading">38 (100)</td><td class="xxxx-borders shading">114 (99)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxr-borders shading">63 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Completed trial — no. (%)</td><td class="xxxx-borders">39 (100)</td><td class="xxxx-borders">38 (100)</td><td class="xxxx-borders">38 (100)</td><td class="xxxx-borders">115 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxr-borders">63 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Were included in the ITT-infected analysis population — no. (%)</td><td class="xxxx-borders shading">25 (64)</td><td class="xxxx-borders shading">31 (82)</td><td class="xxxx-borders shading">30 (79)</td><td class="xxxx-borders shading">86 (75)</td><td class="xxxx-borders shading">15 (71)</td><td class="xxxx-borders shading">11 (52)</td><td class="xxxx-borders shading">12 (57)</td><td class="xxxr-borders shading">38 (60)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Were included in the PK analysis population — no. (%)</td><td class="xxxx-borders shading">38 (97)</td><td class="xxxx-borders shading">38 (100)</td><td class="xxxx-borders shading">38 (100)</td><td class="xxxx-borders shading">114 (99)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxx-borders shading">21 (100)</td><td class="xxxr-borders shading">63 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Were included in the safety analysis population — no. (%)</td><td class="xxxx-borders">39 (100)</td><td class="xxxx-borders">38 (100)</td><td class="xxxx-borders">38 (100)</td><td class="xxxx-borders">115 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxx-borders">21 (100)</td><td class="xxxr-borders">63 (100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">28.5±5.84</td><td class="xxxx-borders shading">27.2±7.50</td><td class="xxxx-borders shading">27.6±7.86</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">23.4±3.22</td><td class="xxxx-borders shading">24.4±5.83</td><td class="xxxx-borders shading">23.1±5.54</td><td class="xxxr-borders shading">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">25 (66)</td><td class="xxxx-borders shading">20 (53)</td><td class="xxxx-borders shading">25 (66)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">11 (52)</td><td class="xxxx-borders shading">10 (48)</td><td class="xxxx-borders shading">12 (57)</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Female</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">18 (47)</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">10 (48)</td><td class="xxxx-borders">11 (52)</td><td class="xxxx-borders">9 (43)</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Race — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Asian</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">White</td><td class="xxxx-borders">33 (87)</td><td class="xxxx-borders">32 (84)</td><td class="xxxx-borders">31 (82)</td><td class="xxxx-borders">—</td><td class="xxxx-borders">18 (86)</td><td class="xxxx-borders">17 (81)</td><td class="xxxx-borders">19 (90)</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23 shading" data-xml-align="left">Other</td><td class="xbxx-borders shading">4 (11)</td><td class="xbxx-borders shading">4 (11)</td><td class="xbxx-borders shading">3 (8)</td><td class="xbxx-borders shading">—</td><td class="xbxx-borders shading">2 (10)</td><td class="xbxx-borders shading">2 (10)</td><td class="xbxx-borders shading">2 (10)</td><td class="xbxr-borders shading">—</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SDs. The intention-to-treat (ITT) analysis population included the participants who were inoculated with respiratory syncytial virus A Memphis 37b (RSV-A M37b), underwent randomization, and received at least one dose of EDP-938 or placebo. The ITT-infected analysis population included the participants in the ITT analysis population who had confirmed RSV-A M37b infection. The pharmacokinetic (PK) analysis population included the participants in the ITT analysis population who had at least one available post-dose PK result. The safety analysis population included all the participants who were inoculated with RSV-A M37b, regardless of whether they would receive a dose of EDP-938 or placebo.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">In part 1 of the trial, 115 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a once-daily 600-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 600-mg once-daily group), a 500-mg loading dose of EDP-938 followed by a 300-mg second dose 11 to 13 hours later and then 300 mg of EDP-938 twice daily (the 300-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">In part 2 of the trial, 63 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a 600-mg loading dose of EDP-938 followed by placebo 11 to 13 hours later and then a once-daily 300-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 300-mg once-daily group), a 400-mg loading dose of EDP-938 followed by a 200-mg second dose 11 to 13 hours later and then 200 mg of EDP-938 twice daily (the 200-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Race was reported by the participants.</div></div></div></figcaption></a><figcaption><div class="caption">Analysis Populations and Baseline Characteristics of the Participants in Trial Parts 1 and 2.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2108903/asset/6f54b883-2ebe-4474-810f-ed45e5dddef2/assets/images/large/nejmoa2108903_t2.jpg" height="2279" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>Part 1</span></th><th class="txxr-borders" colspan="3"><span>Part 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">600-mg<br>Once-Daily Group<br>(N=25)</th><th class="xxxx-borders">300-mg<br>Twice-Daily Group<br>(N=31)</th><th class="xxxx-borders">Placebo<br>Group<br>(N=30)</th><th class="xxxx-borders">300-mg<br>Once-Daily Group<br>(N=15)</th><th class="xxxx-borders">200-mg<br>Twice-Daily Group<br>(N=11)</th><th class="xxxr-borders">Placebo<br>Group<br>(N=12)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">AUC for the mean RSV viral load by RT-qPCR — hr×log<sub>10</sub> copies/ml</td><td class="xxxx-borders shading">204.0±173.5</td><td class="xxxx-borders shading">217.7±217.6</td><td class="xxxx-borders shading">790.2±408.8</td><td class="xxxx-borders shading">173.9±194.8</td><td class="xxxx-borders shading">196.2±124.1</td><td class="xxxr-borders shading">879.0±325.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Standard error</td><td class="xxxx-borders">34.7</td><td class="xxxx-borders">39.1</td><td class="xxxx-borders">74.6</td><td class="xxxx-borders">50.3</td><td class="xxxx-borders">37.4</td><td class="xxxr-borders">94.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference from placebo</td><td class="xxxx-borders shading">−588.1</td><td class="xxxx-borders shading">−564.6</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−716.1</td><td class="xxxx-borders shading">−736.2</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−719.8 to −456.4</td><td class="xxxx-borders">−689.2 to −440.0</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−879.9 to −552.2</td><td class="xxxx-borders">−916.4 to −556.1</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">P value</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Least-squares mean difference between EDP-938 groups</td><td class="xxxx-borders">−23.5</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">20.2</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">95% CI</td><td class="xxxx-borders shading">−154.3 to 107.4</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−150.1 to 190.4</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">P value</td><td class="xxxx-borders">0.70</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">0.80</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">AUC for the mean total symptom score — hr×score</td><td class="xxxx-borders shading">124.5±115.6</td><td class="xxxx-borders shading">181.8±248.4</td><td class="xxxx-borders shading">478.8±422.3</td><td class="xxxx-borders shading">99.3±180.1</td><td class="xxxx-borders shading">89.6±167.7</td><td class="xxxr-borders shading">432.2±342.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Standard error</td><td class="xxxx-borders">23.1</td><td class="xxxx-borders">44.6</td><td class="xxxx-borders">77.1</td><td class="xxxx-borders">46.5</td><td class="xxxx-borders">50.6</td><td class="xxxr-borders">98.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference from placebo</td><td class="xxxx-borders shading">−355.9</td><td class="xxxx-borders shading">−326.6</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−314.0</td><td class="xxxx-borders shading">−312.7</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−506.1 to −205.7</td><td class="xxxx-borders">−469.7 to −183.6</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−494.3 to −133.7</td><td class="xxxx-borders">−508.1 to −117.4</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference between EDP-938 groups</td><td class="xxxx-borders shading">−29.3</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−1.3</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−179.2 to 120.7</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−185.5 to 183.0</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Mean total weight of nasal mucus — g</td><td class="xxxx-borders shading">13.0±13.0</td><td class="xxxx-borders shading">7.4±11.1</td><td class="xxxx-borders shading">33.4±37.8</td><td class="xxxx-borders shading">3.0±4.4</td><td class="xxxx-borders shading">4.7±6.0</td><td class="xxxr-borders shading">22.4±20.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Standard error</td><td class="xxxx-borders">2.6</td><td class="xxxx-borders">2.0</td><td class="xxxx-borders">6.9</td><td class="xxxx-borders">1.1</td><td class="xxxx-borders">1.8</td><td class="xxxr-borders">5.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference from placebo</td><td class="xxxx-borders shading">−24.1</td><td class="xxxx-borders shading">−26.0</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−18.1</td><td class="xxxx-borders shading">−19.3</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−36.6 to −11.6</td><td class="xxxx-borders">−37.7 to −14.2</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−27.2 to −9.1</td><td class="xxxx-borders">−29.1 to −9.6</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference between EDP-938 groups</td><td class="xxxx-borders shading">1.9</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">1.2</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−10.6 to 14.3</td><td class="xxxx-borders">—</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−8.3 to 10.7</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">AUC for the mean RSV viral load by CBI assay — hr×log<sub>10</sub> PFU/ml</td><td class="xxxx-borders shading">34.1±63.6</td><td class="xxxx-borders shading">35.9±78.0</td><td class="xxxx-borders shading">185.6±161.7</td><td class="xxxx-borders shading">23.7±81.8</td><td class="xxxx-borders shading">26.1±39.1</td><td class="xxxr-borders shading">244.0±138.01</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Standard error</td><td class="xxxx-borders">12.7</td><td class="xxxx-borders">14.0</td><td class="xxxx-borders">29.5</td><td class="xxxx-borders">21.1</td><td class="xxxx-borders">11.8</td><td class="xxxr-borders">39.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference from placebo</td><td class="xxxx-borders shading">−153.1</td><td class="xxxx-borders shading">−143.7</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">−207.6</td><td class="xxxx-borders shading">−209.1</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">95% CI</td><td class="xxxx-borders">−208.6 to −97.7</td><td class="xxxx-borders">−196.2 to −91.1</td><td class="xxxx-borders">—</td><td class="xxxx-borders">−281.7 to −133.6</td><td class="xxxx-borders">−288.0 to −130.1</td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Least-squares mean difference between EDP-938 groups</td><td class="xxxx-borders shading">−9.45</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">1.4</td><td class="xxxx-borders shading">—</td><td class="xxxr-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">95% CI</td><td class="xbxx-borders">−64.7 to 45.7</td><td class="xbxx-borders">—</td><td class="xbxx-borders">—</td><td class="xbxx-borders">−73.2 to 76.1</td><td class="xbxx-borders">—</td><td class="xbxr-borders">—</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. The least-squares mean differences in the treatment effect and the 95% confidence intervals (CIs) were obtained from fitting an analysis-of-covariance model to the end point with the trial group as a main effect and the baseline value of the end-point measure as a covariate. The data were normally distributed, and arithmetic means are presented. The least-squares mean difference between EDP-938 groups was calculated as the value in the once-daily EDP-938 group minus the value in the twice-daily EDP-938 group. AUC denotes area under the curve, CBI cell-based infectivity, PFU plaque-forming unit, and RT-qPCR reverse-transcriptase–quantitative polymerase chain reaction.</div></div></div></figcaption></a><figcaption><div class="caption">Efficacy Results in Trial Parts 1 and 2 (ITT–Infected Analysis Population).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2108903/asset/913997e5-cd88-4c03-8c54-47e6902528a3/assets/images/large/nejmoa2108903_t3.jpg" height="2389" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="3"><span>Part 1</span></th><th class="txxr-borders" colspan="3"><span>Part 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">600-mg<br>Once-Daily Group<br>(N=38)</th><th class="xxxx-borders">300-mg<br>Twice-Daily Group<br>(N=38)</th><th class="xxxx-borders">Placebo<br>Group<br>(N=38)</th><th class="xxxx-borders">300-mg<br>Once-Daily Group<br>(N=21)</th><th class="xxxx-borders">200-mg<br>Twice-Daily Group<br>(N=21)</th><th class="xxxr-borders">Placebo<br>Group<br>(N=21)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Adverse events — no.</td><td class="xxxx-borders shading">29</td><td class="xxxx-borders shading">30</td><td class="xxxx-borders shading">41</td><td class="xxxx-borders shading">17</td><td class="xxxx-borders shading">19</td><td class="xxxr-borders shading">14</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants with adverse events — no. (%)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">20 (53)</td><td class="xxxx-borders">21 (55)</td><td class="xxxx-borders">21 (55)</td><td class="xxxx-borders">8 (38)</td><td class="xxxx-borders">10 (48)</td><td class="xxxr-borders">11 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Participants with grade 1 adverse events</td><td class="xxxx-borders shading">20 (53)</td><td class="xxxx-borders shading">20 (53)</td><td class="xxxx-borders shading">18 (47)</td><td class="xxxx-borders shading">7 (33)</td><td class="xxxx-borders shading">10 (48)</td><td class="xxxr-borders shading">9 (43)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Participants with grade 2 adverse events</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Participants with ≥1 adverse event possibly related to trial regimen — no. (%)<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">4 (11)</td><td class="xxxx-borders shading">10 (26)</td><td class="xxxx-borders shading">10 (26)</td><td class="xxxx-borders shading">3 (14)</td><td class="xxxx-borders shading">2 (10)</td><td class="xxxr-borders shading">3 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Participants with ≥1 adverse event possibly related to RSV-A M37b — no. (%)<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">11 (29)</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">2 (10)</td><td class="xxxx-borders">7 (33)</td><td class="xxxr-borders">7 (33)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Participants with the most common adverse events reported — no. (%)<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Increase in alanine aminotransferase level</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Catheter site–related reaction</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Decrease in appetite</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">1 (5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Dizziness</td><td class="xxxx-borders shading">4 (11)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (10)</td><td class="xxxr-borders shading">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Dyspepsia</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Ear pain</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Decrease in forced expiratory volume</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">4 (11)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxr-borders shading">2 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Musculoskeletal chest pain</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (10)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">1 (5)</td><td class="xxxx-borders shading">3 (14)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Rash</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Skin irritation</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">4 (11)</td><td class="xxxx-borders">1 (5)</td><td class="xxxx-borders">2 (10)</td><td class="xxxr-borders">1 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Viral upper respiratory tract infection</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (10)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xbxx-borders">0</td><td class="xbxx-borders">1 (3)</td><td class="xbxx-borders">1 (3)</td><td class="xbxx-borders">1 (5)</td><td class="xbxx-borders">0</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The safety analysis population included 115 participants in part 1 and 63 participants in part 2. An adverse event was listed if it occurred after the start of the trial regimen (the first oral dose of EDP-938 was administered 12 hours after confirmation of a positive nasal-wash sample by RT-qPCR assay) in 2 or more participants receiving EDP-938 or placebo or both across parts 1 and 2. Safety was assessed throughout the duration of the trial up to follow-up day 31.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Grade 1 adverse events were considered to be those that led to a mild level of discomfort and did not interfere with the performance of regular activities; grade 2 adverse events, those that led to a moderate level of discomfort and considerably interfered with the performance of regular activities; and grade 3 adverse events, those that led to a severe level of discomfort and prevented the performance of regular activities. Grade 2 adverse events that occurred in part 1 included dyspepsia in 1 participant in the 300-mg twice-daily group and hypoacusis (in 1 participant) and headache (in 2 participants) in the placebo group. Grade 2 adverse events that occurred in part 2 included paresthesia at the venipuncture site in 1 participant in the 300-mg once-daily group and increased aspartate aminotransferase level (in 1 participant) and headache (in 1 participant) in the placebo group. There were no adverse events of worse severity than moderate.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Whether an adverse event was possibly related to a trial regimen or to RSV-A M37b was determined by the principal investigator.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">The most common adverse events were considered to be those that occurred in 3 or more participants.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events in Trial Parts 1 and 2 (Safety Analysis Population).<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t4"><figure class="table"><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t4.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2108903/asset/5aa564d4-d635-424b-9008-0ce2ed67e26e/assets/images/large/nejmoa2108903_t4.jpg" height="2725" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Measure</th><th class="txxx-borders" colspan="2"><span>Part 1<a href="#core-t4fn2" role="doc-noteref">†</a></span></th><th class="txxr-borders" colspan="2"><span>Part 2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">600-mg<br>Once-Daily Group<br>(N=38)</th><th class="xxxx-borders">300-mg<br>Twice-Daily Group<br>(N=35)</th><th class="xxxx-borders">300-mg<br>Once-Daily Group<br>(N=21)</th><th class="xxxr-borders">200-mg<br>Twice-Daily Group<br>(N=20)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">C<sub>max</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — ng/ml</td><td class="xxxx-borders">1740</td><td class="xxxx-borders">1480</td><td class="xxxx-borders">1010</td><td class="xxxr-borders">901</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">52.8</td><td class="xxxx-borders shading">33.4</td><td class="xxxx-borders shading">15.9</td><td class="xxxr-borders shading">27.9</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Median T<sub>max</sub> — hr</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">4.52</td><td class="xxxx-borders shading">4.10</td><td class="xxxx-borders shading">4.98</td><td class="xxxr-borders shading">4.04</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Min–max</td><td class="xxxx-borders">1.9–17.0</td><td class="xxxx-borders">0.0–10.1</td><td class="xxxx-borders">1.0–15.9</td><td class="xxxr-borders">0.0–10.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Half-life</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — hr</td><td class="xxxx-borders">14.5</td><td class="xxxx-borders">13.8</td><td class="xxxx-borders">14.5</td><td class="xxxr-borders">13.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">25.4</td><td class="xxxx-borders shading">27.4</td><td class="xxxx-borders shading">31.3</td><td class="xxxr-borders shading">23.5</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">CL<sub>ss/F</sub></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean — liters/hr</td><td class="xxxx-borders shading">26.9</td><td class="xxxx-borders shading">24.1</td><td class="xxxx-borders shading">21.3</td><td class="xxxr-borders shading">25.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">%GCV</td><td class="xxxx-borders">44.8</td><td class="xxxx-borders">28.4</td><td class="xxxx-borders">17.6</td><td class="xxxr-borders">23.9</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">V<sub>ss/F</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — liters</td><td class="xxxx-borders">560</td><td class="xxxx-borders">476</td><td class="xxxx-borders">442</td><td class="xxxr-borders">491</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">42.8</td><td class="xxxx-borders shading">23.1</td><td class="xxxx-borders shading">24.1</td><td class="xxxr-borders shading">28.8</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">C<sub>12</sub></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean — ng/ml</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">822</td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">525</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">%GCV</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">35.2</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">30.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">C<sub>24</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — ng/ml</td><td class="xxxx-borders">491</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">287</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">46.9</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">31.6</td><td class="xxxr-borders shading">NA</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">AUC<sub>0–last</sub></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean — hr×ng/ml</td><td class="xxxx-borders shading">32,000</td><td class="xxxx-borders shading">27,300</td><td class="xxxx-borders shading">20,500</td><td class="xxxr-borders shading">17,800</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">%GCV</td><td class="xxxx-borders">52.9</td><td class="xxxx-borders">40.8</td><td class="xxxx-borders">32.1</td><td class="xxxr-borders">29.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">T<sub>last</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — hr</td><td class="xxxx-borders">76.9</td><td class="xxxx-borders">66.1</td><td class="xxxx-borders">76.6</td><td class="xxxr-borders">65.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xxxx-borders shading">11.0</td><td class="xxxx-borders shading">11.3</td><td class="xxxx-borders shading">13.7</td><td class="xxxr-borders shading">12.1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">AUC<sub>0–12</sub></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Geometric mean — hr×ng/ml</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">12,600</td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">8030</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">%GCV</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">29.2</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">24.9</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">AUC<sub>0–24</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Geometric mean — hr×ng/ml</td><td class="xxxx-borders">22,700</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">14,100</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">%GCV</td><td class="xbxx-borders shading">45.7</td><td class="xbxx-borders shading">NA</td><td class="xbxx-borders shading">18.4</td><td class="xbxr-borders shading">NA</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t4fn1" role="paragraph" data-to-manipulate="true">Values are presented as the geometric mean, with the percentage of geometric coefficient of variation (%GCV), for all measures except T<sub>max</sub>, for which the values are presented as the median, with the minimum–maximum (min–max) range. The %GCV was calculated as the square root of the back-transformed standard deviation of plasma concentration of EDP-938 and is expressed as percentage. AUC<sub>0–12</sub> denotes area under the plasma concentration–time curve (time 0 to 12 hours), AUC<sub>0–24</sub> area under the plasma concentration–time curve (time 0 to 24 hours), AUC<sub>0–last</sub> area under the plasma concentration–time curve (time 0 to last quantifiable concentration), C<sub>12</sub> plasma concentration at 12 hours, C<sub>24</sub> plasma concentration at 24 hours, C<sub>max</sub> maximum observed plasma concentration, CL<sub>ss/F</sub> apparent systemic clearance, NA not applicable, T<sub>last</sub> time to the first measurable nonzero concentration, T<sub>max</sub> time to reach the maximum plasma concentration, and V<sub>ss/F</sub> volume of distribution at steady state.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t4fn2" role="paragraph" data-to-manipulate="true">In part 1, the plasma concentrations were below the limit of quantification in 1 participant in the 300-mg twice-daily group.</div></div></div></figcaption></a><figcaption><div class="caption">Plasma Pharmacokinetic Measures of EDP-938 after Administration of the Last Dose in Trial Parts 1 and 2 (PK Analysis Population).<a href="#core-t4fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t4"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2108903_t4.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2108903</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Meissner HC. Viral bronchiolitis in children. <em>N Engl J Med</em> 2016;374:62-72.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2108903&amp;key=10.1056%2FNEJMra1413456&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26735994/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000367580500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Viral+bronchiolitis+in+children.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=62-72&amp;doi=10.1056%2FNEJMra1413456&amp;pmid=26735994" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Tong S, Amand C, Kieffer A, Kyaw MH. Incidence of respiratory syncytial virus related health care utilization in the United States. <em>J Glob Health</em> 2020;10:020422-020422.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7189/jogh.10.020422" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33110581/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000612476300134" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence+of+respiratory+syncytial+virus+related+health+care+utilization+in+the+United+States.&amp;publication_year=2020&amp;journal=J+Glob+Health&amp;pages=020422-020422&amp;doi=10.7189%2Fjogh.10.020422&amp;pmid=33110581" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] older adults, and immunocompromised adults. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] 80% of RSV cases across all age groups. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory syncytial virus seasonality — United States, 2014–2017. <em>MMWR Morb Mortal Wkly Rep</em> 2018;67:71-76.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm6702a4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29346336/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000422763400004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Respiratory+syncytial+virus+seasonality+%E2%80%94+United+States%2C+2014%E2%80%932017.&amp;publication_year=2018&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=71-76&amp;doi=10.15585%2Fmmwr.mm6702a4&amp;pmid=29346336" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Centers for Disease Control and Prevention. Respiratory syncytial virus-associated mortality (RSV-associated mortality): 2019 case definition. 2021 (<a href="https://ndc.services.cdc.gov/case-definitions/respiratory-syncytial-virus-associated-mortality-2019/">https://ndc.services.cdc.gov/case-definitions/respiratory-syncytial-virus-associated-mortality-2019/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Respiratory+syncytial+virus-associated+mortality+%28RSV-associated+mortality%29%3A+2019+case+definition.&amp;publication_year=2021" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] older adults, and immunocompromised adults. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with RSV infections occur annually. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] among children younger than 5 years of age. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. <em>Lancet</em> 2017;390:946-958.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)30938-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28689664/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408746300024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global%2C+regional%2C+and+national+disease+burden+estimates+of+acute+lower+respiratory+infections+due+to+respiratory+syncytial+virus+in+young+children+in+2015%3A+a+systematic+review+and+modelling+study.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=946-958&amp;doi=10.1016%2FS0140-6736%2817%2930938-8&amp;pmid=28689664" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. <em>Cochrane Database Syst Rev</em> 2007;1:CD000181-CD000181.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17253446/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000243747900114" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ribavirin+for+respiratory+syncytial+virus+infection+of+the+lower+respiratory+tract+in+infants+and+young+children.&amp;publication_year=2007&amp;journal=Cochrane+Database+Syst+Rev&amp;pages=CD000181-CD000181&amp;pmid=17253446" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Lee N, Lui GCY, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. <em>Clin Infect Dis</em> 2013;57:1069-1077.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/cit471" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23876395/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325168100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High+morbidity+and+mortality+in+adults+hospitalized+for+respiratory+syncytial+virus+infections.&amp;publication_year=2013&amp;journal=Clin+Infect+Dis&amp;pages=1069-1077&amp;doi=10.1093%2Fcid%2Fcit471&amp;pmid=23876395" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Bollani L, Baraldi E, Chirico G, et al. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). <em>Ital J Pediatr</em> 2015;41:97-97.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13052-015-0203-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26670908/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366457700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revised+recommendations+concerning+palivizumab+prophylaxis+for+respiratory+syncytial+virus+%28RSV%29.&amp;publication_year=2015&amp;journal=Ital+J+Pediatr&amp;pages=97-97&amp;doi=10.1186%2Fs13052-015-0203-x&amp;pmid=26670908" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Challa S, Scott AD, Yuzhakov O, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. <em>Antimicrob Agents Chemother</em> 2015;59:1080-1087.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/AAC.04119-14" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25451060/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348610000040" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanism+of+action+for+respiratory+syncytial+virus+inhibitor+RSV604.&amp;publication_year=2015&amp;journal=Antimicrob+Agents+Chemother&amp;pages=1080-1087&amp;doi=10.1128%2FAAC.04119-14&amp;pmid=25451060" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Rhodin MHJ, McAllister NV, Castillo J, et al. EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. <em>PLoS Pathog</em> 2021;17(3):e1009428-e1009428.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.ppat.1009428" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33720995/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000629666900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EDP-938%2C+a+novel+nucleoprotein+inhibitor+of+respiratory+syncytial+virus%2C+demonstrates+potent+antiviral+activities+in+vitro+and+in+a+non-human+primate+model.&amp;publication_year=2021&amp;journal=PLoS+Pathog&amp;pages=e1009428-e1009428&amp;doi=10.1371%2Fjournal.ppat.1009428&amp;pmid=33720995" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the viral nucleoprotein (N protein). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is distinct from RSV fusion inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] as compared with vehicle control. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Adda N, Dickerson D, Sanderson K, Ahmad A. EDP-938, a novel, non-fusion replication inhibitor of respiratory syncytial virus: preliminary results of a phase 1 study in healthy subjects (HS). Presented at the 11th International Respiratory Syncytial Virus Symposium, Asheville, NC, October 31–November 4, 2018. P104.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Adda+N%2C+Dickerson+D%2C+Sanderson+K%2C+Ahmad+A.+EDP-938%2C+a+novel%2C+non-fusion+replication+inhibitor+of+respiratory+syncytial+virus%3A+preliminary+results+of+a+phase+1+study+in+healthy+subjects+%28HS%29.+Presented+at+the+11th+International+Respiratory+Syncytial+Virus+Symposium%2C+Asheville%2C+NC%2C+October+31%E2%80%93November+4%2C+2018.+P104." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] 18 hours across multiple dosing regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for 7 days without evident safety concerns. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] those observed in the first-in-human study. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Kelly G, Laxton C, Garelnabi M, et al. Use of qualitative integrative cycler PCR (qicPCR) to identify optimal therapeutic dosing time-points in a respiratory syncytial virus human viral challenge model (hVCM). <em>J Virol Methods</em> 2015;224:83-90.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jviromet.2015.08.019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26335961/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000361864000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+qualitative+integrative+cycler+PCR+%28qicPCR%29+to+identify+optimal+therapeutic+dosing+time-points+in+a+respiratory+syncytial+virus+human+viral+challenge+model+%28hVCM%29.&amp;publication_year=2015&amp;journal=J+Virol+Methods&amp;pages=83-90&amp;doi=10.1016%2Fj.jviromet.2015.08.019&amp;pmid=26335961" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. <em>BMJ</em> 1990;300:230-235.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.300.6719.230" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2106931/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1990CL02400023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Analysis+of+serial+measurements+in+medical+research.&amp;publication_year=1990&amp;journal=BMJ&amp;pages=230-235&amp;doi=10.1136%2Fbmj.300.6719.230&amp;pmid=2106931" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Marty FM, Chemaly RF, Mullane KM, et al. A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the lower respiratory tract. <em>Clin Infect Dis</em> 2020;71:2787-2795.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/ciz1167" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31915807/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000607829500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+2b%2C+randomized%2C+double-blind%2C+placebo-controlled+multicenter+study+evaluating+antiviral+effects%2C+pharmacokinetics%2C+safety%2C+and+tolerability+of+presatovir+in+hematopoietic+cell+transplant+recipients+with+respiratory+syncytial+virus+infection+of+the+lower+respiratory+tract.&amp;publication_year=2020&amp;journal=Clin+Infect+Dis&amp;pages=2787-2795&amp;doi=10.1093%2Fcid%2Fciz1167&amp;pmid=31915807" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Ison MG. Optimum timing of oseltamivir: lessons from Bangladesh. <em>Lancet Infect Dis</em> 2014;14:88-89.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(13)70287-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24268592/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330420400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Optimum+timing+of+oseltamivir%3A+lessons+from+Bangladesh.&amp;publication_year=2014&amp;journal=Lancet+Infect+Dis&amp;pages=88-89&amp;doi=10.1016%2FS1473-3099%2813%2970287-1&amp;pmid=24268592" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. <em>Lancet Infect Dis</em> 2014;14:109-118.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(13)70267-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24268590/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330420400024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+oseltamivir+treatment+started+within+5+days+of+symptom+onset+to+reduce+influenza+illness+duration+and+virus+shedding+in+an+urban+setting+in+Bangladesh%3A+a+randomised+placebo-controlled+trial.&amp;publication_year=2014&amp;journal=Lancet+Infect+Dis&amp;pages=109-118&amp;doi=10.1016%2FS1473-3099%2813%2970267-6&amp;pmid=24268590" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">McLean HQ, Belongia EA, Kieke BA, Meece JK, Fry AM. Impact of late oseltamivir treatment on influenza symptoms in the outpatient setting: results of a randomized trial. <em>Open Forum Infect Dis</em> 2015;2(3):ofv100.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/ofid/ofv100" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26258157/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365786500026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+late+oseltamivir+treatment+on+influenza+symptoms+in+the+outpatient+setting%3A+results+of+a+randomized+trial.&amp;publication_year=2015&amp;journal=Open+Forum+Infect+Dis&amp;doi=10.1093%2Fofid%2Fofv100&amp;pmid=26258157" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 16, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2118465" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">The Challenge of Respiratory Syncytial Virus Human Challenge Studies</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">L.J. Anderson and E.E. Walsh</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Farmington, Maine</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885453/urologist-physician-mainehealth-urology-farmington-me/?query=fjwp&amp;rid=1000">Urologist - Physician - MaineHealth Urology - Farmington, ME</a></div></div><div class="nejm-widget_item"><div><span> Manhasset, New York</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/652131/body-imaging-physician-scientist/?query=fjwp&amp;rid=3059">Body Imaging Physician-Scientist</a></div></div><div class="nejm-widget_item"><div><span> Fort Morgan, Colorado</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883461/physician-family-medicine/?query=fjwf&amp;rid=129661">Physician Family Medicine</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Dermatology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880629/dermatology-opening-in-scenic-western-massachusetts-no-call/?query=fjwf&amp;rid=5127">Dermatology Opening in Scenic Western Massachusetts - No Call</a></div></div><div class="nejm-widget_item"><div><span> New Hampshire</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893399/new-england-employed-gastroenterology/?query=fjwf&amp;rid=5263">New England Employed Gastroenterology</a></div></div><div class="nejm-widget_item"><div><span> Philadelphia, Pennsylvania</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886162/instructor/?query=fjwf&amp;rid=271428">Instructor</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2108903&amp;pubId=41284251&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6bf7a523b1aed-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6bf7a523b1aed-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6bf7a523b1aed-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$913135004$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$913135004$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$913135004$--></div></div><div class="mlt-body"><!--?lit$913135004$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$913135004$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$913135004$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$913135004$-->Sep 26, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2313551?query=recirc_Semantic" target="_self">Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection</a></div><div class="mlt-article-authors"><!--?lit$913135004$-->S. Zhao and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/editorial?query=recirc_Semantic" target="_self"><!--?lit$913135004$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$913135004$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$913135004$-->Feb 25, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDe2400440?query=recirc_Semantic" target="_self">Nirsevimab for Respiratory Syncytial Virus Prophylaxis in Newborns and Infants</a></div><div class="mlt-article-authors"><!--?lit$913135004$-->B. Resch</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$913135004$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$913135004$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$913135004$-->Jul 30, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1908380?query=recirc_Semantic" target="_self">Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants</a></div><div class="mlt-article-authors"><!--?lit$913135004$-->S.A. Madhi and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$913135004$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$913135004$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$913135004$-->Feb 16, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2209604?query=recirc_Semantic" target="_self">Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults</a></div><div class="mlt-article-authors"><!--?lit$913135004$-->A. Papi and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$913135004$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$913135004$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$913135004$-->Jun 23, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2116154?query=recirc_Semantic" target="_self">Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study</a></div><div class="mlt-article-authors"><!--?lit$913135004$-->B. Schmoele-Thoma and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2108903?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2108903" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2108903.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2108903"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2116133" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMra2034954" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Electroconvulsive Therapy</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2108903_f1.jpg"><img src="/cms/10.1056/NEJMoa2108903/asset/65155284-a088-4147-9214-36dbeb3f8404/assets/images/large/nejmoa2108903_f1.jpg" height="3272" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Viral Load, Clinical Symptoms, and Mucus Weight in Trial Parts 1 and 2.</div><div class="notes"><div role="doc-footnote">Shown are the mean (±SE) respiratory syncytial virus loads, total symptom scores, and mucus weight from the time immediately before administration of the first dose until 10 days afterward in the intention-to-treat–infected analysis population, which included the participants who had been inoculated with the respiratory syncytial virus A Memphis 37b strain, had received at least one dose of EDP-938 or placebo, and had confirmed infection. In part 1 of the trial, 115 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a once-daily 600-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 600-mg once-daily group), a 500-mg loading dose of EDP-938 followed by a 300-mg second dose 11 to 13 hours later and then 300 mg of EDP-938 twice daily (the 300-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours. In part 2 of the trial, 63 participants received EDP-938, placebo, or both twice daily over 5 consecutive days for a total of 10 doses. The participants were randomly assigned in a 1:1:1 ratio to receive a 600-mg loading dose of EDP-938 followed by placebo 11 to 13 hours later and then a once-daily 300-mg dose of EDP-938 followed by placebo at intervals of 11 to 13 hours (the 300-mg once-daily group), a 400-mg loading dose of EDP-938 followed by a 200-mg second dose 11 to 13 hours later and then 200 mg of EDP-938 twice daily (the 200-mg twice-daily group), or placebo twice daily at intervals of 11 to 13 hours. The total symptom score is the sum of the scores for all 10 symptoms that were listed in the diary card and assessed by the participants 3 times daily. The score for each symptom ranged from 0 to 3, with higher scores indicating greater severity (additional details are provided in Section 10.7.2.1 of the statistical analysis plan, available with the <a href="#ap1">protocol</a> at NEJM.org). CBI denotes cell-based infectivity, PFU plaque-forming unit, and RT-qPCR reverse-transcriptase–quantitative polymerase chain reaction.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Analysis Populations and Baseline Characteristics of the Participants in Trial Parts 1 and 2.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Efficacy Results in Trial Parts 1 and 2 (ITT–Infected Analysis Population).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events in Trial Parts 1 and 2 (Safety Analysis Population).<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t4" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 4</div><div class="fv__item__description"><figcaption><div class="caption">Plasma Pharmacokinetic Measures of EDP-938 after Administration of the Last Dose in Trial Parts 1 and 2 (PK Analysis Population).<a href="#fv-t4fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/386/7" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 386 No. 7</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 17, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2117175" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J. Kanter and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 17, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2116596" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.R. Bishop and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 17, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2116133" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">F.L. Locke and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2108903%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2108903&amp;pubId=41284251&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2108903%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2108903&amp;pubId=41284251&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id0842217935407209" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6bf7a523b1aed-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6bf7a523b1aed-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6bf7a523b1aed-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6bf7a523b1aed-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6bf7a523b1aed-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6bf7a523b1aed-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6bf7a523b1aed-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6bf7a523b1aed-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6bf7a523b1aed-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6bf7a523b1aed-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6bf7a48cd1aed',t:'MTc0OTUzNjI3MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6bf7a48cd1aed&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><ims-nxphrzlfbslj></ims-nxphrzlfbslj><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2108903?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-transactionid="wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" id="captureIFrame_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" target="captureIFrame_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="capture_screen"><input id="capture_signIn_js_version_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="js_version"><input id="capture_signIn_transactionId_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" type="hidden" class="capture_transactionId_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="capture_transactionId"><input id="capture_signIn_form_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="form"><input id="capture_signIn_flow_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="flow"><input id="capture_signIn_client_id_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="client_id"><input id="capture_signIn_redirect_uri_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="redirect_uri"><input id="capture_signIn_response_type_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="response_type"><input id="capture_signIn_flow_version_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="flow_version"><input id="capture_signIn_settings_version_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="settings_version"><input id="capture_signIn_locale_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="locale"><input id="capture_signIn_recaptcha_version_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_wgwckik5121qw13lgeyxf1v0ampuvuby2wby1jwd" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>